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Interrogating the molecular mechanisms of breast cancer metastasis: the 




Devin Thomas Rosenthal 
 
 
Chair: Sofia D. Merajver 
 
Breast cancer lethality is primarily due to cancer cell metastasis away from the 
primary tumor to vital organs. Understanding and targeting the molecular 
mechanisms contributing to metastasis is therefore essential to combating the 
disease. Here we focus on two main mechanisms by which molecules contribute 
to metastasis—as either metastatic initiators (genes that can catalyze the shift 
from tumorigenic to metastatic) or metastatic perpetuators (genes that maintain, 
but cannot independently initiate, the metastatic state).  
 
We discovered that RhoC GTPase is both necessary and sufficient for breast 
cancer stem cell metastasis. Surprisingly, RhoC was capable of initiating 
metastasis independent of primary tumor formation, which attests to its strength 
as a metastatic initiator. In addition to governing breast cancer stem cell 
metastatic potential, we also found that RhoC affects the abundance of breast 
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cancer stem cells within a population. Together these data establish RhoC as the 
first identified initiator of breast cancer stem cell metastasis. 
 
In separate studies, we discovered that p38γ MAPK perpetuates breast cancer 
metastasis and specifically impacts the mesenchymal-like behaviors of 
aggressive breast cancer cells. Interestingly, we found that p38γ is connected to 
RhoC, as changes in p38γ expression concurrently alter RhoC expression by 
affecting RhoC ubiquitination and lysosomal degradation. These findings are 
clinically relevant, as high p38γ expression was associated with both the basal-
like breast cancer subtype as well as poorer overall patient survival. 
 
Using computational modeling alongside cell biology we revealed that p38γ 
modulates cell motility by regulating actin stress fiber organization. In doing so 
we also discovered a novel physical behavior of motile cells—leading edge 
protrusion oscillations—which we verified both experimentally and 
computationally. Through in silico modeling we were able to deduce a likely 
sequence of events leading from p38γ knockdown to the observed motility 
phenotype. 
 
Taken together, this body of work defines a new subset of breast cancer stem 
cells that act as metastatic initiators—metastatic breast cancer stem cells, driven 
by RhoC expression—and characterizes a novel metastatic perpetuator in p38γ. 
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This work opens many new research avenues which we discuss and elaborate 






The normal mammary gland undergoes dramatic remodeling throughout a 
woman‘s life: invasive expansion through adipose tissue during puberty, 
widespread proliferation of lobules during pregnancy, and subsequent apoptosis 
during involution. Precise temporal and spatial control of these processes is 
essential for proper growth and development of the mammary gland. Deviation 
from this developmental blueprint leads to aberrant breast epithelial cell growth—
which may be the beginnings of breast cancer. 
 
Breast cancer presents as a dysplastic disease of mammary epithelial cells, 
which can grow abnormally for years yet remain confined within mammary ducts 
or lobules. Confinement of malignant epithelial cells within the ductolobular 
network is an important barrier to breast cancer progression. As long as 
malignant cells remain contained within the ducts or lobules, patient survival 
remains relatively high; approximately 98% of patients diagnosed with localized 
breast cancer will not suffer from cancer recurrence within 5 years (1). 
 
Breast cancer prognosis dramatically worsens once cells invade out of the 
ductolobular network and into the surrounding stroma. The 5-year probability of
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 survival for regionally invasive breast cancer (breast cancer that has spread to 
regional lymph nodes) is only 83%—a 15% decrease from localized breast 
cancer (1). After exiting the ducts or lobules, cancer cells can metastasize via the 
blood or lymphatic systems to distant organs such as the lungs, liver, or bones. 
The presence of distant metastases at the time of diagnosis carries the worst 
prognosis: a mere 23% of patients will survive 5 years post-diagnosis (1). 
Targeting this final, lethal stage of breast cancer progression is therefore 
paramount for improving patient outcome. 
 
* * * 
 
The metastatic process begins with malignant epithelial cells breaking through 
the myoepithelial cell and basement membrane layers that enclose the ducts and 
lobules. Although the specifics of the interactions between breast carcinoma and 
myoepithelial cells during breast cancer progression remains poorly understood 
(2, 3), the overall effect is clear: once carcinoma cells traverse the myoepithelial 
cell barrier, patient outcome worsens (2). 
 
In addition to crossing the myoepithelial cell barrier, a metastasizing cell must 
also break through the proteinaceous basement membrane enveloping the 
mammary ductolobular network. In the mammary gland, the basement 
membrane is primarily composed of collagens, laminins, and heparin sulfate 
proteoglycans that are secreted by the myoepithelial cells (4). The pores formed 
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by these matrix proteins are too small for cells to fit through; therefore, 
metastasizing cells must cleave these protein fibers in order to traverse the 
basement membrane. This is accomplished by expressing and secreting 
proteases, such as MMP-2, -9, and -14, which degrade the basement membrane 
and allow the metastasizing cell to pass through and enter the adipose-rich 
breast stroma (5). 
 
Details of the steps in metastatic progression between initial escape from the 
primary tumor and colonization of a distant metastatic site are currently poorly 
understood. In general, after escaping from the mammary ducts or lobules, the 
metastasizing cell follows chemotactic signals from the blood or lymphatic 
system to locate vessels (6). Upon reaching the vasculature, the metastasizing 
cell enters the blood or lymphatic system by the process of intravasation (6, 7).    
 
Early reports revealed clinically relevant links between the numbers of circulating 
tumor cells and patient survival (8-10), however little is known about the actual 
behavior of cancer cells in circulation. Metastatic circulating breast cancer most 
commonly manifests clinically in the bone, brain, lungs, and liver. Upon reaching 
one of these sites, a successful metastasizing breast cancer cell exits the 
vasculature through the process of extravasation. Once it has entered the 
metastatic site, the metastasizing cell shifts its cellular program from the invasive, 
motile behavior that allowed it to escape the confines of the primary tumor back 
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to a stationary, proliferative profile that enables it to colonize its new 
environment.  
 
A similar plasticity in behavior occurs during normal development through a 
process known as the epithelial-mesenchymal transition (EMT). The EMT is a 
hallmark of normal developmental processes, such as mesoderm formation 
during gastrulation and wound healing. As the name implies, the EMT involves 
epithelial cells acquiring properties characteristic of mesenchymal cells—namely 
cell differentiation markers such as vimentin intermediate filaments, a shift from 
stationary to motile and invasive, and an accompanying change in cell shape 
from rounded to elongated (11). The EMT is reversible through a process known 
as mesenchymal-to-epithelial transition (MET), and epithelial cells that undergo 
an EMT may undergo a MET upon completion of their designated task (11, 12). 
 
Cancer cells appear to harness the EMT to facilitate local invasion and ultimately 
metastasis (11, 13, 14); for example, cells at the invasive front of a tumor 
express mesenchymal markers, such as vimentin and smooth muscle actin. 
Accordingly, master regulators of the EMT, such as Twist, have been shown to 
induce breast cancer metastasis (15). Inhibition of twist specifically prevents 
breast cancer metastasis, while ectopic expression in non-tumorigenic mammary 
epithelial cells induces an EMT and increases cell motility. As expected based on 
the association between mesenchymal differentiation and metastatic properties, 
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the most aggressive breast cancer molecular subtypes are those that are the 
most mesenchymal-, or basal-, like (16). 
 
Recently, the potential contribution of EMT to cancer has been shown to have 
some possible relation to cancer stem cells. The cancer stem cell hypothesis 
postulates that many cancers are maintained by a small population of variably 
pluripotent cells within the tumor, termed cancer stem cells (CSCs), which 
possess unlimited replication potential as well as the ability to self renew. The 
CSC hypothesis further postulates that cancers are hierarchically organized, with 
CSCs residing at the top of the hierarchy. Pioneering work by Michael Clarke and 
Max Wicha demonstrated that breast CSCs (BCSCs) can be identified by specific 
cell surface markers or enzymatic activity (17, 18) and that the BCSC population 
is the tumorigenic population in xenografted mice. Recent work has also 
suggested that CSCs may be resistant to conventional therapies (19); therefore, 
standard chemotherapy may eliminate the bulk population of non-CSCs but leave 
behind the minority CSC population, which is then capable of repopulating the 
tumor. Taken together, these properties of CSCs have led researchers to 
hypothesize that BCSCs drive breast cancer and are the major cause of cancer 
recurrence (20). 
 
Elegant work by Mani et al. uncovered a link between EMT and CSCs (21). The 
group demonstrated that inducing EMT in human mammary epithelial cells 
(HMECs) causes these cells to express stem cell markers and behave like stem 
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cells. Inducing EMT in transformed HMECs generates CSCs and increases 
transformed HMEC tumorigenicity. They also discovered that breast stem cells 
and CSCs express EMT markers, suggesting that EMT may play a contributing 
role in the CSC phenotype. This convergence of concepts—CSCs in tumor 
growth, EMT in cancer metastasis, and the interrelatedness of the two—opens 
the possibility that CSCs, like EMT, are involved in cancer metastasis. 
 
Early work on CSCs and metastasis uncovered circumstantial links, such as the 
connection between CSCs and EMT reported by Mani et al. (21), and prior work 
identifying an invasiveness gene signature in the BCSC population that predicted 
shorter metastasis-free survival (22). Recent studies have provided stronger 
correlative evidence linking CSCs and metastasis. Liu et al. revealed that the 
relative abundance of BCSCs is increased in spontaneous breast cancer 
metastases in an orthotopic xenograft model (23), and Charafe-Jauffret et al. 
found that BCSCs mediate metastasis of the most aggressive subset of breast 
cancer, inflammatory breast cancer (IBC) (24). In line with these studies, 
subpopulations within the CSC population, delineated by specific surface marker 
expression, have been identified that are required for metastasis of several types 
of cancer (25, 26). This correlative evidence provides solid support for CSCs 
functioning in metastasis, however to date there is no functional molecular link 
between BCSCs and metastasis. 
 




Understanding the switch from tumorigenesis to metastasis—and subsequently 
elucidating the genes that empower metastatic cells—is fundamental to 
controlling breast cancer. The body of work presented here interrogates breast 
cancer metastasis by focusing on two essential questions: which genes cause a 
cell to metastasize, and which genes contribute to the metastatic properties of a 
metastasizing cell? 
 
The distinction between these two questions is subtle, yet highly pertinent. From 
tumor inception a cancer cell functions as a proliferative machine; multiplying 
within the tissue of origin, resistant to normal growth-inhibitory signals. By 
contrast, a metastasizing cell is programmed for movement; escape from the 
primary tumor, travel through the vasculature to distant organs, and ultimately 
colonization of a new environment. Certain genes drive the fundamental 
behaviors associated with each of these cell programs, yet most of these genes 
alone are not sufficient to induce a programmatic switch—from tumorigenesis to 
metastasis, or vice versa. 
 
Viewing metastasis from this perspective reveals two principle points for 
therapeutic intervention: either preventing metastasis by targeting the transition 
from tumorigenesis to metastasis, or impairing the progress of already metastatic 
cells. Each of these approaches holds potential, but each is important for a 




Case 1: A 32 year-old woman presents with DCIS with microinvasion and 2/40 
positive lymph nodes. She is treated with aggressive chemotherapy and 
hormonal therapy, which causes her tumor to regress. Shortly after ending 
therapy, however, her tumor recurs, spreads to 12/40 lymph nodes, and 
metastasizes to her lungs. 
 
Case 2: A 42 year-old woman presents with widely invasive, metastatic triple-
negative breast cancer and 10/40 positive lymph nodes.  
 
In Case 1, the patient presents with locally invasive breast cancer—aggressive 
cancer, but not yet fully metastatic. Treatment with chemotherapy and hormonal 
therapy successfully eliminates the disease in the short term; however, the 
cancer later recurs as highly metastatic, aggressive breast cancer.   
 
Case 1 is an example of a patient that would benefit from targeting the transition 
from tumorigenesis to metastasis. Although her cancer is locally invasive, the 
cells have not yet become fully metastatic. While the majority of the patient‘s 
tumor was eliminated by the combination of chemotherapy and hormonal 
therapy, a few cancer cells likely resisted treatment and remained dormant in her 
breast. Once these cells became active again they switched programs, from 
tumorigenic to metastatic, and disseminated throughout her body. Such a case is 
consistent with the CSC hypothesis (accounting for the few resistant cancer cells 
9 
 
capable of regenerating the disease), and the concept of a switch between 
tumorigenic and metastatic CSCs.  
 
In Case 2, the patient presents with metastatic breast cancer. These cancer cells 
have already undergone the transition from tumorigenic to metastatic, so 
preventing this transition would minimally benefit the patient. Case 2 is an 
example of a patient that would benefit from impairing the progress of already 
metastatic cells. By elucidating and targeting the molecular perpetuators of these 
already metastatic breast cancer cells, the clinician could hope to restrict the 
metastatic, and ultimately lethal, spread of the patient‘s tumor—thus opening the 
possibility of surgical or chemotherapeutic intervention to effectively combat the 
disease. 
 
* * * 
 
Referring to our earlier description of the metastatic process, there is one 
property of metastasizing cells that persists throughout most stages of metastatic 
progression: cell motility. Mammary epithelial cells in the developing mammary 
gland are sessile, save for invasive outgrowth during puberty. The same holds 
true in a primary tumor, as cell energy is instead directed towards rapid and 
uncontrolled proliferation. Although many other abilities are needed for a cell to 
metastasize (invasion to traverse the basement membrane, anchorage-
independent growth to survive in the circulation, and so forth), all stages of 
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metastatic progression, save for final colonization, require a stationary cell to 
acquire the ability to move. 
 
Such a transition between stationary and motile occurs throughout development 
by the aforementioned EMT—the same process involved in breast cancer 
progression. In agreement with their having undergone an EMT, metastasizing 
breast cancer cells are able to rapidly move through diverse stroma and tissues 
using a mesenchymal-like mode of motility. 
 
Mesenchymal cell motility is broadly characterized by repeated cycles of 
contractile-based motion. The process can be broken into four key phases: 1) 
leading edge protrusion leading to cell elongation, 2) formation of focal adhesions 
at the leading edge, 3) initiation of actomyosin contraction, and 4) dissolution of 
focal adhesions at the trailing edge, resulting in retraction of the trailing edge and 
rapid whole cell movement. It is interesting to note the parallels between 
mesenchymal motility and muscle contraction; namely, the use of actomyosin-
based contractility to generate productive movement, whether of a muscle or a 
cell. We will return to and elaborate on this point later in the chapter, as this 
fundamental similarity serves as the basis for our hypothesis regarding breast 
cancer metastasis in chapters 3 and 4.  
 
The four-step motility cycle outlined above repeats cyclically to generate 
productive, directed cell movement. Because of its cyclic nature, any step of this 
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cycle could be designated the initial step; for the purpose of the data to be 
presented here we will begin with leading edge protrusion. Below we elaborate 
on each phase of motion: 
 
Leading edge protrusion and focal adhesion formation 
Forward protrusion of a cell‘s leading edge is driven by actin polymerization in 
the form of either lamellipodial or pseudopodial structures. Underlying both 
structures is the requisite of focal adhesions anchored to the extracellular 
substratum. For reference, these components, as well as many of their regulatory 
proteins, are outlined in Figure 1.1. Once bound to the substratum, the 
immobilized focal adhesions bind and anchor existing actin filaments, providing a 
stable foundation against which polymerizing actin filaments are able to generate 
protrusive force (Figure 1.2). Conversely, detachment of focal adhesions from 
either the actin filaments or the substrate permits leading edge retraction by 
retrograde flow (Figure 1.2). 
 
In general, cells will first extend small, finger-like pseudopodial protrusions, 
termed filopodia, to probe the surrounding environment. Filopodia are composed 
of parallel actin filaments tightly bundled together, with the barbed ends (the ends 
onto which actin monomers can be added) of the filaments facing towards the 
cell membrane (27). Filopodia are responsible for detecting chemo- and 
mechanotactic environmental cues and for forming focal adhesions, and thus 




The lamellipodium, by contrast, is composed of a thin, branched actin meshwork 
that, along with the lamella, generates protrusion across the entire leading edge 
of a cell (29, 30). Despite this morphologic difference, the underlying mechanism 
of protrusion remains the same; actin polymerization against focal adhesions 
generates protrusions, while retrograde flow permits retraction (31). 
 
Focal adhesion composition 
As described in the previous section, focal adhesion formation is essential for cell 
movement. Focal adhesions are the physical and biochemical links between the 
cell and its environment. They are large, macromolecular structures composed of 
up to 100 different proteins, depending on the nature of the focal adhesion (32). 
In general, though, focal adhesions consist of three principle components: 
integrins, adaptor proteins, and intracellular signaling proteins.  
 
Integrins are heterodimeric transmembrane proteins that bind to the extracellular 
matrix, linking it to the intracellular environment (33). There are many different 
forms of integrins, each of which is specific for a particular extracellular matrix 
component (i.e. fibronectin, collagen, and others). Adaptor proteins, such as talin 
and vinculin, bind to the intracellular domain of an integrin and link it to the 
cytoskeleton. The integrin-adaptor protein-cytoskeleton complex then recruits 
and binds to various intracellular signaling proteins, such as focal adhesion 




Actomyosin contraction and focal adhesion dissolution 
Once the leading edge of a cell has been extended by actin protrusion and 
anchored by the formation of new focal adhesions, the trailing edge of the cell 
must detach and retract in order for the cell to complete its movement. Myosin 
contained within the stress fibers generates the contractile forces that initiate this 
process. The contraction mechanism functions similarly to the protrusion 
mechanism in that actomyosin contractile force is generated by pulling (rather 
than pushing, in the case of protrusion) against stable focal adhesions at the 
leading and trailing regions of the cell (31).  
 
Detachment of focal adhesions at the trailing edge can occur by one of two 
mechanisms. Trailing edge focal adhesions can be dissolved by releasing their 
attachment to the microenvironment, uncoupling from the cytoskeleton, and 
ultimately being broken down within the cell into their component proteins (35, 
36). Alternatively, in some cell types integrins permanently adhere to the 
substratum; therefore they instead detach from the cytoskeleton and are 
ultimately left behind, adhered to the substratum, as the cell moves on (37, 38). 
 
* * * 
 
These phases of cell motility are regulated at many levels by hundreds of 
different proteins (39, 40); however, the majority of these processes are 
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regulated by members the Ras homologous (Rho) protein family. Rho family 
GTPases comprise the largest subfamily cluster of the Ras-homology 
superfamily of small GTPases (~21 kDa). Currently, 22 Rho family entries are 
annotated in the ENTREZ database, which can be divided into 10 different 
groups on the basis of their sequence homology to either Cdc42, Rac1, RhoA, 
RhoD, Rif/RhoF, Rnd3/RhoE, TTF/RhoH, Chp/RhoV or RhoBTB.  
 
Like most Ras homology proteins, Rho GTPases function as molecular switches 
– GTP-bound Rho proteins are active, GDP bound Rho proteins are inactive. 
Thus, Rho-GTP binds and activates downstream effectors leading to a variety of 
signaling cascades, while Rho-GDP does not. 
 
Cycling between GTP- and GDP-bound states is tightly controlled by three 
different classes of Rho regulatory proteins: GTPase-activating proteins (GAPs), 
guanine nucleotide dissociation inhibitors (GDIs), and guanine nucleotide 
exchange factors (GEFs). GAPs and GDIs inhibit Rho activity - GAPs by 
accelerating Rho protein hydrolysis of GTP into GDP, and GDIs by sequestering 
Rho proteins to the cytoplasm and blocking GDP dissociation – while GEFs 
activate Rho proteins by triggering the release of GDP from Rho-GDP, thereby 
permitting the Rho protein to bind GTP. 
 
The activation of Rho-family proteins is mediated through a wide array of 
mechanisms including interactions with G-protein-coupled receptors (GPCRs) 
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and other cell surface receptors, such as cytokine, tyrosine kinase, and adhesion 
receptors. Once initiated, Rho signaling leads to the activation of several different 
pathways depending on the precursor signal, the cellular context, and the 
crosstalk with other activated or repressed pathways. In fact, when Rho-family 
proteins were first brought into the limelight following landmark publications by 
Ridley, Hall, and their coworkers in 1992, the number of publications on the 
diversity of functions of Rho proteins rose exponentially (41, 42). In these papers, 
Ridley and Hall related the assembly of focal adhesions and actin stress fibers to 
growth factor signaling through Rho GTPase. Since then, Rho proteins have also 
been shown to play roles in adhesion, migration, phagocytosis, cytokinesis, 
neurite extension and retraction, cell morphogenesis and polarization, growth 
and cell survival (43-46). Additionally, aberrant overexpression of some Rho-
family proteins, such as RhoC, has been shown to promote malignant 
transformation and metastasis. 
 
RhoC is responsible for coordinating cell motility by regulating actomyosin 
contractility and focal adhesion turnover (40, 47, 48). Although highly 
homologous to RhoA, RhoC has distinct contributions to cell motility and cancer, 
such as playing a larger role in stress fiber formation and contraction than RhoA 
(49). RhoC expression also increases post-EMT and was required for post-EMT 
motility of colon carcinoma cells, whereas RhoA expression decreased and 




In cancer, RhoC is a potent metastatic driver of many cancer types (51-54), and 
RhoC knockout selectively inhibits metastasis—independent from primary tumor 
formation—in a transgenic breast cancer model (55). In agreement with these 
previous findings, unpublished data from our lab suggests that RhoC 
overexpression also affects breast cancer metastasis. Specifically, crossing mice 
expressing mouse mammary tumor virus (MMTV)-driven RhoC in the mammary 
gland with either of two tumorigenic and metastatic transgenic mouse models—
the Her2/neu and polyoma middle-T models—increases the incidence of lung 
metastasis and the number of metastases present without appreciably affecting 
tumor incidence or growth (unpublished observations).. 
 
Earlier work from our lab sought to identify signaling pathways involved in 
mediating RhoC-induced metastatic behavior. This analysis revealed that the p38 
mitogen activated protein kinase (MAPK) pathway was involved in RhoC-
mediated motility, invasion, and angiogenesis (56). 
 
The MAPK pathway consists of three branches – ERK, JNK, and p38 – which are 
responsible for integrating extracellular stimuli and translating them into cellular 
responses by phosphorylating a network of downstream effector proteins (57). 
The canonical MAPK signaling cascade consists of three levels. The MAPKs 
(ERK, JNK, and p38) are at the end of the cascade, preceded by the MAPK 
kinases (MAP2Ks) and the MAPK kinase kinases (MAPK3Ks), respectively. 
Signals from various extracellular stimuli are transmitted to the MAPK3Ks, which 
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phosphorylate (and thus activate) the MAPK2Ks, which subsequently 
phosphorylate the MAPKs, which then proceed to phosphorylate a plethora of 
downstream effectors to enact behaviors as diverse as proliferation, motility, 
apoptosis, and differentiation (58). 
  
Despite the nomenclature, ERK is the only member of the MAPK family that 
responds to mitogenic signals. JNK and p38, by comparison, are activated by 
genotoxic and environmental stresses as well as inflammation, and accordingly 
are also referred to as stress activated protein kinases (SAPKs) (58, 59). 
 
The p38 arm of the MAPK pathway is effected by four closely related isoforms: 
p38 α, β, γ and δ. Based on protein sequence homology p38 α and β cluster 
together, as do p38 γ and δ. Despite their sequence similarity and shared 
upstream kinases, the p38 isoforms can have unrelated, and even antagonistic, 
roles in development and disease (59-63). These disparate results appear to be 
due to both context dependence (cell type, signal specificity, and others), as well 
as oft-ignored isoform-specific functions. 
 
The vast majority of studies focusing on the p38 pathway utilize pyridinyl 
imidazole inhibitors such as SB203580, which act as competitive inhibitors by 
binding to the ATP pocket of p38 (64). Though highly effective and easily 
administered in vitro, this class of inhibitors only targets the α and β isoforms; 
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thus most knowledge about p38 signaling focuses on these two isoforms, often 
without differentiating between them.  
 
With the advent of RNA interference technologies, isoform-specific p38 studies 
emerged. Interestingly, the non-canonical p38 isoforms, specifically p38δ, have 
been shown to promote and regulate tumorigenic and metastatic properties (65-
67). Cancer research focused on p38γ has still remained quite limited however, 
despite studies implicating it in cancer-related properties such as maintenance of 
intercellular junctions (68) and progenitor cell expansion (69).  
 
p38γ (also referred to as MAPK12, ERK6, or SAPK3) is a 42 kDa member of the 
p38 MAPK family that is activated by cytokines, such as IL-1 and TNFα, and 
cellular stresses, such as osmotic shock and inhibition of protein synthesis (70). 
Unlike the other p38 isoforms, which are ubiquitously expressed, p38γ 
expression is restricted to muscle tissue, where its primary function is to promote 
myoblast differentiation into myogenic precursor cells and myotubes (69, 71-74). 
Though highly homologous to the other three p38 isoforms, p38γ has a unique c-
terminal –ETXL sequence that enables binding to PDZ domains within PDZ 
domain-containing proteins such as human discs large (hDlg), SAP90, and 
SAP97 (68, 75-77). PDZ domains serve to localize PDZ domain-containing 
proteins to specific subcellular sites, where they often function as connections 
between transmembrane proteins and the cytoskeleton (75), suggesting that 
p38γ may interact with the cytoskeleton. Based on its developmental roles in 
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muscle cell differentiation and its suggested association with the cytoskeleton, it 
is tempting to speculate that p38γ may function in regulating mesenchymal-like 
cellular motility, such as that used by metastasizing breast cancer cells.  
 
Indeed, p38γ has been shown to have oncogenic functions. On a correlative 
level, p38γ mRNA is overexpressed in several types of cancer (78, 79). p38γ has 
been shown to bind the PDZ domain of the phosphatase PTPH1, and their 
binding and interaction facilitates Ras-induced oncogenesis (80). Additionally, 
p38γ is the only member of the p38 family that is induced by Ras activation (78, 
81), and its expression helps increase Ras-induced cancer invasion (81, 82). 
 
* * * 
 
As discussed earlier, we view the overarching questions regarding breast cancer 
metastasis as: which genes cause a cancer cell to metastasize, and which genes 
contribute to the metastatic properties of a metastasizing cell? Based on the 
body of work surrounding the signaling molecules discussed in the previous 
section, we proposed two hypotheses aimed at addressing these two questions. 
 
As discussed earlier in this chapter, the EMT is required for stationary epithelial 
cells to acquire mesenchymal-like motility properties. Additionally, the EMT can 
induce epithelial cells to acquire stem cell-like properties, and carcinoma cells to 
become cancer stem cells (21). As stated in the previous section, RhoC is a 
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potent inducer of cell motility, invasion, and metastasis—all hallmark behaviors of 
mesenchymal cells, and accordingly of carcinoma cells that have undergone 
EMT. Additionally, RhoC expression was shown to increase post-EMT and 
promote post-EMT motility of colon carcinoma cells. In light of these established 
functions for RhoC, the link between RhoC and the EMT, and the recently 
identified interrelationship between the EMT and cancer stem cells, we 
hypothesized that RhoC might contribute to the metastatic properties of breast 
cancer stem cells. 
 
As implied by the name, under normal developmental conditions the EMT is 
utilized to change an epithelial cell into a mesenchymal cell. Interestingly, the 
behavior of mesenchymal cells—particularly their contractility-based mode of 
locomotion—shares many similarities with the contractile behavior of muscles. 
Indeed, the mesoderm layer formed by the EMT and subsequent invagination of 
the ectoderm layer during gastrulation eventually gives rise to muscles in the 
body. It is therefore a logical prediction to reason that genes which mediate 
muscle differentiation may also function in establishing muscle-like, or 
mesenchymal-like, behavior in other cell types. Based on this reasoning, we 
hypothesized that p38γ may promote mesenchymal-like cell behavior in breast 
carcinoma cells and thus promote metastasis. 
 




Chapter 2: RhoC determines the metastatic potential and affects the 
abundance of breast cancer stem cells 
In this chapter we address the question ―which genes allow a cancer cell to 
metastasize?‖ By specifically inhibiting RhoC in a metastatic breast cancer cell 
line and overexpressing RhoC in a non-tumorigenic, non-metastatic mammary 
epithelial cell line we were able to determine that RhoC is both necessary for and 
sufficient to induce metastasis of breast cancer stem cells—making RhoC the 
first identified molecular initiator of BCSC metastasis. Surprisingly, we also 
discovered that RhoC expression and activity of the BCSC marker ALDH1 are 
tightly intertwined, as changes in RhoC expression directly influence the 
abundance of BCSCs, and conversely RhoC expression is primarily restricted to 
the ALDH (+) BCSC population. Furthermore, expression of RhoC and ALDH1 
was tightly correlated in breast cancer patient tissue samples, suggesting that the 
relationship between these two proteins may indeed hold clinical relevance.  
 
Chapter 3: p38γ regulates breast cancer cell motility and metastasis 
through modulation of RhoC GTPase 
Here we address the question ―which genes contribute to the metastatic 
properties of a metastasizing cell?‖ We observed that p38γ is overactivated in a 
panel of basal (or mesenchymal-like) breast cancer cell lines. By inhibiting p38γ 
using two types of RNA interference and by overexpression of a dominant 
negative construct, we determined that p38γ contributes to the metastatic 
abilities of basal breast cancer cells, both in vitro and in vivo. Surprisingly, we 
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discovered that p38γ modulates RhoC expression by a novel mechanism—
regulation of RhoC ubiquitination, and consequently lysosomal degradation. We 
extended this research into the clinical setting and revealed that the relationship 
between RhoC and p38γ persists in human breast cancer patients, and that p38γ 
is associated with the basal breast cancer subtype and lower overall patient 
survival. 
 
Chapter 4:  Computational mechanical modeling reveals the role of p38γ in 
shaping the cytoskeleton and controlling locomotion of aggressive breast 
cancer cells  
Here we extend the work of the previous chapter and take an alternative 
approach to the traditional ―mechanistic‖ study by exploring the physical 
behaviors, rather than signaling molecules, underlying the relationship between 
p38γ, the actin cytoskeleton, and cell motility. By computationally modeling basal 
breast cancer cell motility we were able to determine that p38γ-mediated 
cytoskeletal changes are central to the motility defects observed following p38γ 
knockdown. In the course of our study the computational models predicted, and 
biological experiments subsequently verified, a novel behavior at the leading 
edge of motile cells: leading edge protrusion oscillations. Subsequent in silico 
analysis revealed a likely sequence of events leading from p38γ knockdown to 
the observed motility defects, thereby mechanistically linking p38γ to the 






Figure 1.1 – Overview of the cytoskeletal components of a motile cell and 
the corresponding regulatory proteins (from Le Clainche and Carlier, 





Figure 1.2 – Focal adhesions act as a “molecular clutch”. Using this clutch 
mechanism focal adhesions direct either (A) retrograde actin flow or (B) 
protrusion (or alternatively trailing edge retraction, as mediated by myosin-based 
contractility) (from Le Clainche and Carlier, Physiological Reviews 2008 (Am 





















Portions of Chapter 1 are found in my book chapter on Rho GTPase signaling 
published in The Rho GTPases in Cancer (2010), pp. 29-42, under the title ―Rho 
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RhoC determines the metastatic potential and affects the abundance of 
breast cancer stem cells 
 
Abstract 
Cancer stem cells have been shown to promote tumorigenesis of many tumor 
types, including breast, although their relevance to cancer metastasis remains 
unclear. While subpopulations of cancer stem cells that are required for 
metastasis have been identified, to date there are no known molecular regulators 
of breast cancer stem cell metastasis. Here we identify RhoC GTPase as an 
essential regulator of breast cancer stem cell metastasis, and present evidence 
that RhoC also modulates the frequency of breast cancer stem cells within a 
population. Using an orthotopic xenograft model of spontaneous metastasis we 
discover that RhoC is both necessary and sufficient to promote breast cancer 
stem cell metastasis, often independent from primary tumor formation. The 
relationship between RhoC and breast cancer stem cells persists in breast 
cancer patients as well, as expression of RhoC and the breast cancer stem cell 
marker ALDH1 are highly correlated in clinical breast cancer specimens. These 
results open new avenues to combating the deadliest cells driving the most lethal 





The cancer stem cell (CSC) hypothesis posits that a small subset of cells within a 
tumor is responsible for maintaining the growth and survival of the cancer. The 
minority CSC population retains a relatively undifferentiated state and possesses 
unlimited replication potential, as well as the ability to both self-renew and 
produce differentiated progeny, and thus aid in generating heterogeneity within a 
tumor (83). Although constituting only a small proportion of total tumor mass, 
CSCs are thought to be the only cells within a tumor capable of sustaining tumor 
growth. CSCs are presumed to be more adept at resisting conventional therapies 
than non-CSCs, and therefore are thought to be the cause of recurrence in many 
patients (19). The presumption that CSCs are resistant to conventional therapies 
and capable of regenerating a tumor thought to be in remission makes targeting 
CSCs of paramount clinical importance. 
 
Despite the local effects of a primary tumor, the actual lethality of many cancers, 
such as breast cancer, is due to metastasis of cells away from the primary tumor 
to vital organs. Intriguingly, recent work has revealed an emerging role for CSCs 
in cancer metastasis. Initial work uncovered circumstantial links between CSCs 
and metastasis, including the presence of an invasiveness gene signature in the 
breast CSC (―BCSC‖) population that predicted shorter metastasis-free survival 
(22), and an association between BCSCs and the metastasis-associated 




Recent studies have demonstrated more causative links between BCSCs and 
metastasis.  A recent publication from Liu et al. revealed that BCSCs are 
enriched within spontaneous breast cancer metastases in an orthotopic xenograft 
model (23), and Charafe-Jauffret et al. found that BCSCs mediate metastasis of 
the most aggressive subset of breast cancer, inflammatory breast cancer (IBC) 
(24). In line with these studies, subpopulations within the CSC population have 
been identified, based on surface marker expression, that selectively enable 
metastasis of several types of cancer (25, 26). While evidence for CSCs having 
an important role in metastasis exists and markers identifying metastatic CSC 
populations are emerging, a functional molecular link between BCSCs and 
metastasis has not yet been identified (84). Here we demonstrate that RhoC 
GTPase promotes BCSC metastasis, and is capable of initiating metastasis 
independent of primary tumor formation. 
 
RhoC is a member of the Rho family of GTPases and is responsible for 
coordinating cell motility by regulating actomyosin contractility and focal adhesion 
turnover (40, 47, 48). In cancer, RhoC has been shown to be a potent metastatic 
driver of many cancer types (51-54), and RhoC knockout selectively inhibits 
metastasis—independent from primary tumor formation—in a transgenic breast 
cancer model (55).  
 
The metastatic influence of RhoC is exemplified by IBC. IBC is the most lethal 
form of breast cancer, and is metastatic from its inception. RhoC was found to be 
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overexpressed in 90% of IBC cases (85), and RhoC overexpression is capable of 
partially recapitulating the IBC phenotype in vitro (51). As mentioned previously, 
BCSCs play an important role in IBC metastasis and are associated with poor 
clinical outcome (24). Based on the strong association between RhoC, BCSCs, 
and metastasis in IBC, we used the IBC-derived SUM149 cell line to address 
RhoC functionality in BCSC metastasis. 
 
Here we discover that RhoC plays an essential role in mediating BCSC 
metastasis. Inhibiting RhoC revealed that it is necessary for BCSC metastasis in 
the highly metastatic SUM149 cell line, and conversely overexpressing RhoC 
alone was sufficient to enable metastasis of BCSCs from the otherwise non-
tumorigenic, non-metastatic MCF-10A cell line. Surprisingly, RhoC often 
promoted spontaneous BCSC metastasis independent from primary tumor 
formation – speaking to RhoC potency as a metastasis-promoting gene. RhoC 
also appears to directly influence the BCSC population size, as the percent of 
BCSCs within each cell line varied concurrent with changes in RhoC expression. 
Expression of RhoC and the BCSC marker ALDH1 strongly correlate in clinical 
breast cancer specimens, suggesting that the link between RhoC and BCSCs 
has therapeutic relevance. To the best of our knowledge RhoC is therefore the 
first identified molecular promoter of BCSC metastasis – one which holds 







RhoC expression is enriched in the ALDH (+) population 
To address the question of whether RhoC functions in the pathogenesis of 
BCSCs, we first asked whether RhoC expression was associated with BCSCs. 
Using the highly aggressive RhoC-overexpressing SUM149 cell line we 
discovered that, after sorting for aldehyde dehydrogenase (ALDH) activity using 
the ALDEFLUOR assay (18), RhoC expression was primarily confined to the 
ALDH (+) BCSC population (Figure 2.1A), introducing the possibility that RhoC is 
preferentially utilized by BCSCs.  
 
To empirically determine whether RhoC functionally contributes to BCSC 
aggressiveness we generated genetically modified cell lines to test the effects of 
inhibiting RhoC in SUM149 cells (―SUM149 shRhoC‖) or overexpressing 
constitutively active RhoC in the non-tumorigenic mammary epithelial cell line 
MCF-10A (―MCF-10A G14V‖) (Figure 2.1B). Importantly, neither modification 
affected expression of the close RhoC homolog RhoA (Figure 2.1B). 
 
Interestingly, when we sorted the modified cell lines for ALDH and observed 
RhoC expression as in Figure 2.1A, we found that RhoC expression was still 
enriched in the ALDH (+) population even within the genetically modified cell 
lines (Figure 2.1C-D). This was surprising, given that these cells were forcibly 
overexpressing (Figure 2.1C) or inhibiting (Figure 2.1D) RhoC. The fact that this 
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dichotomy in RhoC expression between the ALDH (+) and (-) populations 
persisted after genetic modification strengthened the case for an association 
between BCSCs and RhoC expression. 
 
Modifying RhoC expression alters the metastatic properties of CSCs in 
vitro 
Upon observing a strong association between RhoC expression and BCSCs, we 
asked whether this relationship had a functional role in governing BCSC 
behavior. The acquisition of motility by otherwise stationary cells is a hallmark of 
cancer progression (86) and a process regulated across many cell lineages and 
cancer types by RhoC (51, 52, 87). Since CSCs have been linked to metastasis, 
albeit indirectly (84), we investigated RhoC effects on BCSC motility using time 
lapse microscopy. 
 
We found that modulating RhoC expression significantly impacted cell velocity, 
even within the ALDH (+) CSC population in each cell line (Figure 2.2A). 
Inhibiting RhoC in highly motile SUM149 cells resulted in a significant reduction 
in cell speed, while overexpressing constitutively active RhoC in slow-moving 
MCF-10A cells significantly increased cell speed. Interestingly, we also observed 
significant changes in cell speed between ALDH (+) and (-) cells within each cell 
line that again paralleled RhoC expression. Decreased RhoC expression in 
SUM149 cells (either by shRNA inhibition, or within the ALDH (-) population) 
reduced cell motility to levels comparable to the non-tumorigenic MCF-10A 
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control cell line (―MCF-10A vec‖). Even in the highly motile MCF-10A G14V cell 
line, ALDH (-) cells (which have lower RhoC G14V expression than ALDH (+) 
cells (Figure 2.1C)) moved significantly slower than ALDH (+) cells. The only cell 
line which did not show a significant difference in cell speed between the ALDH 
(+) and (-) populations was the MCF0-10A vec cell line. We note that this is not 
entirely unexpected, as this cell line is non-tumorigenic, slow-moving, and 
expresses low endogenous levels of RhoC (Figure 2.1B-C). 
 
Three-dimensional Matrigel cell culture is frequently used as a tool to observe 
physiologically-relevant developmental, tumorigenic, and metastatic behaviors of 
mammary epithelial cells and breast cancer cells in vitro (88, 89). We employed 
this technique to broadly assess the cancerous properties of the RhoC-modified 
and ALDH-sorted cells. As has previously been observed for MCF-10A cells (88, 
89), unsorted MCF-10A vec cells formed small, well-defined acinar structures 
(Figure 2.2B, first column, second row)—the in vitro representation of a normal, 
non-tumorigenic mammary gland. By contract, SUM149 scrambled cells grew as 
large, disorganized cell clusters that formed invasive protrusions into the 
surrounding matrix (Figure 2.2B, first column, third row)—growth characteristic of 
tumorigenic, metastatic breast cancer cells (89, 90).  
 
Modifying RhoC expression had a significant and similar impact on the in vitro 
metastatic phenotype of both unsorted cell lines. MCF-10A G14V acinar-like 
structures were more disorganized than their vector control counterparts, with 
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cells invading outward from the central mass (Figure 2.2B, first column, first row), 
similar to SUM149 scrambled cells. Also of note was the slightly increased size 
of the MCF-10A G14V structures compared to the MCF-10A vec acini. 
Conversely, SUM149 shRhoC cells formed structures of comparable size to 
SUM149 scrambled cells; however, these structures had well-defined borders, 
showing minimal evidence of cell invasion into the matrix (Figure 2.2B, first 
column, fourth row). 
 
The effects of sorting for ALDH once again mirrored RhoC expression within 
each cell line.  The ALDH (+) population of each cell line (Figure 2.2B, second 
column) grew similarly to the unsorted population (Figure 2.2B, first column), 
whereas the ALDH (-) population appeared both non-tumorigenic and non-
invasive in all cell lines (Figure 2.2B, third column). Of note, although some 
colonies in the SUM149 scrambled ALDH (-) population still formed large acinar-
like structures, these structures had well-defined borders with no signs of 
invasive behavior (Figure 2.2B, third column, third row). Taken together, these 
data support a role for RhoC in mediating metastatic behaviors of the ALDH (+) 
BCSC population. 
 
Modulating RhoC expression results in concurrent changes in CSC 
abundance 
In the course of ALDH-sorting for our in vitro experiments we made a surprising 
observation: there appeared to be a RhoC-dependent change in BCSC 
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abundance in each cell line. To further investigate this observation, we compared 
the relative abundance of ALDH (+) BCSCs in each control cell line (SUM149 
scrambled or MCF-10A vec) to the corresponding RhoC-modified cell line 
(SUM149 shRhoC or MCF-10A G14V). Surprisingly, we observed almost 
identical reciprocal differences between the two groups: a two-fold decrease in 
the ALDH (+) population of SUM149 shRhoC compared to scrambled, and a two-
fold increase in the ALDH (+) population of MCF-10A G14V compared to vector 
(Figure 2.2C), suggesting that RhoC plays a role in determining the abundance 
of BCSCs within a population. 
 
RhoC expression dictates metastasis of BCSCs 
Based on our in vitro observations, we asked whether RhoC affects the behavior 
of BCSCs in vivo. To address this question we orthotopically xenografted 
NOD/SCID mice with either 50 ALDH-sorted SUM149 scrambled or shRhoC 
cells, or 5000 ALDH-sorted MCF-10A vec or G14V cells, and observed the 
incidence of tumorigenesis and metastasis. 
 
Inhibiting RhoC in SUM149 cells caused a significant decrease in tumor 
incidence in the ALDH (+) population (see Table 2.1). 5 out of 9 (55.6%) SUM149 
scrambled control mice developed tumors, whereas none of the eight mice 
injected with SUM149 shRhoC cells formed tumors (p = 0.029). There was no 
significant difference in tumor incidence between the ALDH (+) MCF-10A vec 
and G14V cell lines, although one MCF-10A G14V mouse did present with a 
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tumor (Table 2.1). At the limiting cell numbers used for this study none of the 
mice injected with ALDH (-) cells formed tumors. 
 
Surprisingly, when we inspected the mice for evidence of metastasis we 
discovered large metastatic tumors completely filling the pleural cavity in many of 
the mice injected with ALDH (+) SUM149 scrambled and MCF-10A G14V cells 
(Figure 2.3Ai). We also observed one instance in the ALDH (+) SUM149 shRhoC 
cohort and two instances in the ALDH (-) MCF-10A G14V cohort (Figure 2.3B 
and Table 2.1). Histologic examination revealed these tumors to be poorly 
differentiated carcinomas, with remarkably similar appearance between the MCF-
10A G14V and SUM149 scrambled metastases (Figure 2.3Aii). In all, 66.67% of 
mice injected with ALDH (+) SUM149 scrambled cells and 90% of mice injected 
with ALDH (+) MCF-10A G14V cells presented with metastases, compared to 
only 12.5% of ALDH (+) SUM149 shRhoC-injected and 33.33% of ALDH (-) 
MCF-10A G14V-injected mice (Table 2.1). 
 
Even more surprising was the propensity for metastasis in mice that did not form 
primary tumors (Figure 2.3A-B). 35% of mice injected with ALDH (+) SUM149 
scrambled cells, and a remarkable 80% of mice injected with ALDH (+) MCF-10A 
G14V cells had metastases independent of primary tumor formation (Figure 
2.3B). Additionally, all of the ALDH (+) SUM149 shRhoC and ALDH (-) MCF-10A 




One central tenant of the CSC hypothesis is that CSCs can self-renew and 
generate heterogeneity within a tumor whereas non-CSCs cannot (83). Based on 
this assumption, we hypothesized that the dichotomy in RhoC expression 
between the ALDH (+) and (-) populations was maintained in vivo, since ALDH (-) 
cells should not be able to restore tumor heterogeneity. We used the SUM149 
scrambled cell line to assay RhoC expression in vivo, as it is the only cell line in 
this study that expresses high levels of endogenous RhoC (Figure 2.1B). 
 
Since none of the mice injected with 50 ALDH (-) SUM149 scrambled cells 
formed tumors we increased the injection to 5000 cells, at which point the ALDH 
(-) population also formed tumors. After allowing tumors to develop we 
euthanized the mice, extracted protein from the tumors, and assayed RhoC 
expression. The dichotomy of RhoC expression between ALDH (+) and ALDH (-) 
tumors persisted in vivo; ALDH (+) SUM149 scrambled tumors maintained RhoC 
expression during tumor growth, whereas ALDH (-) SUM149 scrambled tumors 
did not regain RhoC expression (Figure 2.2C). This data supports the assertion 
that ALDH (-) cells are indeed non-CSCs, and accordingly have a decreased 
ability to form tumors and/or metastasis (Figure 2.3B and Table 2.1) and are 
unable to restore tumor heterogeneity, as demonstrated by their inability to re-
express RhoC after expansion in vivo (Figure 2.3C). Along with our previous 
findings illustrating the influence of RhoC on CSC abundance (Figure 2.2C), this 
data further supports the conclusion that RhoC expression is intimately linked to 




RhoC and ALDH1 expression are highly correlated in clinical breast cancer 
samples 
Expression of the ALDH1 protein has been shown to be a reliable marker for 
BCSCs in paraffin-embedded tissue (18). To extend our findings on the 
relationship between RhoC and BCSCs, we used Automated Quantitative 
Analysis (AQUA) of immunofluorescence signals for RhoC and ALDH1 in 
cytokeratin-positive cells from a breast cancer tissue microarray. Expression of 
RhoC and ALDH1 were strongly positively correlated in the 136 samples 
analyzed (Figure 2.3D), indicating that the tight association between RhoC and 




CSCs have been shown to promote tumorigenesis in numerous cancer types 
(17, 91, 92), and recent work has begun to define a role for CSCs in cancer 
metastasis as well (23-26). Despite the established therapeutic importance of 
targeting metastasis and the growing understanding of the role of CSCs in 
metastasis, to date no functional molecular regulators have been identified that 
promote aggressive, metastatic behavior of BCSCs. Here we identify RhoC as 




By approaching RhoC expression from two distinct angles—its necessity for 
metastasis of a breast cancer cell line (SUM149), and its sufficiency to induce 
metastasis of a non-tumorigenic mammary epithelial cell line (MCF-10A)—we 
were able to clearly elucidate a role for RhoC in BCSC metastasis. It is important 
to note that we used an orthotopic xenograft system rather than an intracardiac 
or tail vein injection assay to measure metastasis. As emphasized in a recent 
publication (23), the orthotopic xenograft model of spontaneous breast cancer 
metastasis is a more physiologically relevant model of breast cancer metastasis 
which more accurately recapitulates the microenvironmental obstacles metastatic 
cells encounter in human patients. 
 
Modulating RhoC expression in either SUM149 or MCF-10A cells had a 
concordant effect on the metastatic potential of BCSCs from each cell line. 
Interestingly, not only did alterations in RhoC expression affect metastasis of the 
BCSCs, but RhoC was preferentially expressed by the BCSC fraction. We further 
found that RhoC expression and BCSC abundance are intertwined, as the 
abundance of BCSCs within a cell line was altered concurrently with modified 
RhoC expression. Further supporting the relationship between RhoC and BCSCs 
is our finding that expression of RhoC and the BCSC marker ALDH1 are strongly 
correlated in clinical breast cancer samples. Taken together, these data reveal a 
close association between RhoC and BCSCs; one in which RhoC expression 
determines BCSC metastatic potential and contributes to determining the 
frequency of BCSCs within a population. This evidence supports the theory that a 
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larger BCSC population (93)—and thus higher RhoC expression —may confer a 
worse prognosis (94). 
 
It is interesting to note that a sizable fraction of mice injected with non-CSC 
ALDH (-) MCF-10A G14V still developed lung metastases (Table 2.1). That these 
cells were still capable of metastasizing further supports RhoC sufficiency to 
induce metastasis. Although the ALDH (-) fraction of the MCF-10A G14V cell line 
had lower RhoC expression, expression was not completely eliminated (Figure 
2.1C), as is to be expected from a cell line forcibly overexpressing a transgene. 
Furthermore, the residual RhoC expression in the ALDH (-) population is 
predominately RhoC G14V—a constitutively active form of RhoC—thus 
amplifying the effect of even low levels of expression. Therefore, the fact that 
several of the ALDH (-) MCF-10A G14V developed metastases is not surprising, 
and is in agreement with the hypothesis that RhoC expression is capable of 
promoting metastasis independent of BCSC status—although under endogenous 
conditions RhoC expression is closely associated with the BCSC population. 
 
In agreement with this assertion we also observed metastasis in one mouse 
injected with ALDH (+) SUM149 shRhoC cells. As we previously observed, RhoC 
is preferentially expressed by the ALDH (+) population (Figures 2.1A, C-D) and 
although we were able to achieve significant RhoC knockdown, RhoC expression 
was not completely eliminated from SUM149 shRhoC cells. Accordingly, the 
remaining RhoC was primarily confined to the ALDH (+) population (Figure 2.1D). 
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Again, though correlative, this evidence supports the hypothesis that RhoC 
expression is both necessary and sufficient for BCSC metastasis. 
 
It is also important to emphasize that, although mice injected with ALDH (-) MCF-
10A G14V developed metastases, they did not develop primary tumors (Table 
2.1). Although RhoC has been shown to function in tumorigenic processes such 
as angiogenesis (95), its primary function, as illustrated by our work here and 
that of others (55), is in driving breast cancer metastasis. We note that IBC is 
metastatic from its inception; therefore the decrease in tumor formation of ALDH 
(+) SUM149 shRhoC compared to SUM149 scrambled cells may be attributable 
to both the early contributions of RhoC-mediated metastatic properties to IBC 
tumorigenesis (such as secretion of angiogenic factors), as well as the minor role 
that RhoC plays in tumorigenesis.  
 
The work presented here provides strong rationale for therapeutically targeting 
RhoC. RhoC has previously been shown to be essential for metastasis in a 
transgenic breast cancer model (55) and is overexpressed in many different 
cancer types (52-54)—in particular IBC (85), which presently lacks effective 
therapies—yet this is the first work to relate RhoC to BCSCs. To this end, our lab 
has designed a small molecule RhoC inhibitor which has shown good in vitro and 
in vivo efficacy with no apparent toxicity (unpublished data). As therapies 
targeting CSCs emerge (96), it will be important to address which CSC 
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populations are being targeted—the tumorigenic or the metastatic population—in 
order to effectively combat the disease. 
 
 
Materials and Methods 
Reagents 
shRNA was purchased from Open Biosystems through the University of Michigan 
Life Science Institute High Throughput Screening Core. For western blotting, the 
following antibodies were used: rabbit anti-RhoC (Cell Signaling), goat anti-actin, 
and mouse anti-RhoA (Santa Cruz Biotechnology). Matrigel and growth factor-
reduced Matrigel were purchased from BD Biosciences. The ALDEFLUOR assay 
kit was purchased from StemCell Technologies. 
 
Cell Culture 
Untransfected cell lines were cultured in Ham‘s F12 (SUM149) supplemented 
with 5% fetal bovine serum, or DMEM/F12 (MCF-10A) supplemented with 10% 
horse serum. Selection media for shRNA-transfected cells consisted of standard 
cell line media containing 1μg/ml puromycin. Selection media for RhoC or RhoC 
G14V-transfected cells consisted of standard cell line media with 350μg/ml G418. 
MCF-10A cells were grown at 37°C in a humidified 5% CO2 incubator, and 




For 3D cell culture, cells were cultured as described by Lee et al. (89). Briefly, 4-
well chamber slides (Lab-Tek) were coated with growth factor-reduced Matrigel 
(BD Biosciences). Cells were plated at a density of 2.1 x 104 cells/cm2 in cell 
media containing 4% Matrigel and cultured for 7 days.  
 
Time-Lapse Microscopy 
DIC time-lapse videos were captured at 37°C using a Deltavision RT Live Cell 
Imaging System at the University of Michigan Microscopy and Image Analysis 
Lab. Images were acquired using SoftWoRx 3.5.1 software. Cell motility videos 
were analyzed using the MTrackJ plugin 
(http://www.imagescience.org/meijering/software/mtrackj/) for ImageJ (97), from 
which the average velocity of each cell line was calculated in μm/hour. 
 
ALDEFLUOR Assay 
The ALDEFLUOR assay was performed according to the manufacturer‘s 
instructions; see also (18). 
 
Orthotopic Xenografts and Metastasis Analysis 
All mouse work was performed in accordance with the University of Michigan‘s 
standards for animal use. After sorting into ALDH (+) and ALDH (-) populations 
with the ALDEFLUOR assay, cells were diluted 1:1 with Matrigel (BD 
Biosciences). NOD/SCID mice were anesthetized and 50 (SUM149 and variants) 
or 5000 (MCF-10A and variants) cells were injected directly into the fourth 
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mammary gland. Tumors were monitored weekly and mice were euthanized 
once tumor volume approached 2 cm3 or mice showed signs of morbidity. Lungs 
were analyzed at the time of euthanization for macroscopic metastases. Tumors 
and lungs were then resected, fixed in 10% formalin, paraffin embedded, and 
stained with hematoxylin and eaosin.  
 
In situ detection and quantification of protein expression 
Tumors and Patients 
Fresh and formalin-fixed, paraffin-embedded tissue blocks (FFPE) of breast 
cancer were obtained from the files of the Department of Pathology, University of 
Michigan Medical Center, Ann Arbor, MI. IRB approval was obtained and the 
diagnosis was confirmed by morphology. After pathological review, a tissue 
microarray was constructed from the most representative area using the 
methodology of Nocito et al. (98). Survival data was obtained from the Cancer 
Registry of The University of Michigan. 
Immunohistochemical Staining and AQUA analysis. 
Triple immunofluorescence staining was performed as previously described (99) 
and the AQUA system (HistoRx, New Haven, Connecticut) was used for the 
automated image acquisition and analysis. The detailed staining and imaging 





All p-values were calculated by Student‘s two-tailed t-test unless otherwise 
noted. Expression levels of ALDH1 and RhoC in TMA samples were compared 




We would like to thank the University of Michigan Cancer Center Flow Cytometry 
core for technical assistance. This work was supported by the Department of 
Defense Breast Cancer Research Program through a Predoctoral Traineeship 
award (BC083262) (D.T.R.), an NIH Cellular and Molecular Biology Training 
Grant (T32-GM07315) (D.T.R.), the Burroughs Wellcome Fund (S.D.M.), and the 





Figure 2.1 – RhoC expression is intimately linked to the ALDH (+) breast 
cancer stem cell population. (A) RhoC expression is directly related to breast 
cancer stem cell status in the highly aggressive, RhoC-overexpressing SUM149 
IBC cell line. ALDH (+) SUM149 cells have high RhoC expression, whereas 
RhoC expression is significantly reduced in the ALDH (-) population. (B) To 
investigate the effect of RhoC expression on breast cancer stem cell behavior we 
knocked down RhoC expression in SUM149 cells and, conversely, 
overexpressed a constitutively active form of RhoC (RhoC G14V) in the low 
RhoC-expressing normal-like mammary epithelial cell line MCF-10A. Importantly, 
modulating RhoC expression did not affect expression of the close homolog 
RhoA. (C-D) Interestingly, even when RhoC is exogenously expressed or 
inhibited in MCF-10A (C) or SUM149 cells (D), RhoC expression still segregates 





Figure 2.2 – RhoC dictates the behavior and abundance of breast cancer 
stem cells. (A) RhoC expression determines cell speed, even within the ALDH 
(+) population. Comparing the ALDH (+) populations of each cell line, modulating 
RhoC expression results in a corresponding change in cell speed (i.e. decreased 
cell speed in 149 shRhoC ALDH (+) compared to 149 scrambled ALDH (+)). 
Comparing between ALDH populations within a cell line, cell speed is decreased 
in the ALDH (-) population, concurrent with RhoC expression (Figure 2.1C-D). 
(B) Cell growth in 3D Matrigel culture reflects RhoC expression. Cells with high 
RhoC expression (149 scrambled and 10A G14V) exhibit aggressive, invasive 
growth in 3D culture, whereas cells with low RhoC expression (149 shRhoC and 
10A vec) do not invade outward into the surrounding matrix (see ―unsorted‖). 
When sorted for ALDH, this invasive outgrowth is restricted to the ALDH (+) 
fraction of the high RhoC-expressing cell lines, suggesting that the 
aggressiveness of ALDH (+) breast cancer cells is reliant on RhoC (scale = 100 
µm). (C) In addition to modifying the behavior of ALDH (+) cells, RhoC 
expression also alters the abundance of ALDH (+) BCSCs within a cell line. The 
percent of ALDH (+) cells is decreased by over 50% in 149 shRhoC compared to 





Figure 2.3 – RhoC expression determines the metastatic potential of ALDH 
(+) breast cancer stem cells. (A) NOD/SCID mice orthotopically xenografted 
with only 50 SUM149 or 5000 MCF-10A RhoC-expressing breast cancer stem 
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cells form large lung metastases, often independent of primary tumor formation. 
i) Arrows indicate injection sites lacking primary tumors, arrowheads indicate 
lung metastases. ii) H&E-staining shows that lung metastases from both MCF-
10A G14V and SUM149 scrambled cells are poorly differentiated, invasive 
carcinomas (scale = 50 µm) (B) Quantitative analysis of xenografted mice 
establishes RhoC as a driving force behind ALDH (+) BCSC lung metastasis 
(also see Table 2.1). MCF-10A cells, which do not have the genetic mutations 
required to initiate primary tumor formation, instead metastasize independent of 
primary tumor formation when forced to overexpress active RhoC (RhoC G14V). 
Note that even ALDH (-) 10A G14V, which have reduced but not completely 
eliminated active RhoC expression, do not form primary tumors but can still 
metastasize, albeit less frequently, than ALDH (+) 10A G14V. Importantly, the 
incidence of cancer drops from greater than 85% in ALDH (+) 149 scrambled and 
10A G14V mice to less than 13% in ALDH (+) 149 shRhoC and 10A vec mice, 
demonstrating the essential role RhoC plays in the aggressiveness of breast 
cancer stem cells in vivo. (C) Injecting mice with 5000 SUM149 scrambled 
cells—at which point both the ALDH (+) and ALDH (-) populations form tumors—
reveals that reduced RhoC expression is maintained in vivo in ALDH (-) tumors. 
This provides mechanistic evidence for the inability of ALDH (-) cells to 
metastasize (their inability to reexpress RhoC), and speaks to the inability of the 
ALDH (-) population to reconstitute tumor heterogeneity. (D) RhoC and ALDH1 
expression are highly correlated in clinical breast cancer samples (Spearman‘s 






Table 2.1 – Analysis of xenografted mice. 
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Supplemental Methods  
Immunohistochemical Staining and AQUA analysis. 
Briefly, after deparaffinization and rehydration, TMA slides were subjected to 
microwave epitope retrieval in 10 mM sodium citrate buffer, pH6. After rinsing 
several times in 10 mM Tris/HCl buffer, pH 8 containing 0.154 M NaCl and 
0.05%(v/v) Tween-20 (TBST), endogenous peroxidase activity was blocked with 
2.5% (v/v) H2O2 in methanol for 30 minutes. Non-specific binding of the 
antibodies was extinguished by a 30 minute incubation with ‗Background Sniper‖ 
(BioCare Medical, Concord, CA). The TMA slide was then incubated with a 
combination of the tumor-specific antibody, cytokeratin (DAKO, Carpinteria, CA, 
rabbit polyclonal antibody, Z0622, 1:250) and ALDH1 (BD Biosciences, mouse 
monoclonal antibody, 611195, 1:100) overnight at 4C. The slides were then 
washed with TBST twice for 5 minutes. The slides were subsequently incubated 
with an antibody to RhoC (chicken IgY polyclonal antibody, 1:1000) for 60 
minutes at room temperature. Slides were then washed as described above and 
incubated with a combination of goat anti rabbit IgG conjugated to AF555 
(Molecular probes, Carpinteria, CA, A21428, 1:200) and goat anti chicken IgY 
conjugated to AF488 (Molecular probes, Carpinteria, CA, A11039, 1:200) in goat 
anti mouse Envision+ (DAKO, Carpinteria, CA, K4001) for 60 minutes at room 
temperature in a dark humidity tray. The slides were then washed as described 
above and the target image was developed by a CSA reaction of Cy5 labeled 
tyramide (PerkinElmer, Waltham, MA, 1:50). The slides were washed with 3 
changes of water and stained with the DNA staining dye 4‘,6-diaminodo-2-
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phenylindole (DAPI) in a non-fading mounting media (ProLong Gold, Molecular 
probes, Carpinteria, CA). The slides were allowed to dry overnight in a dark dry 
chamber and the edges were sealed. 
 
For AQUA, images of each TMA core were captured with an Olympus BX51 
microscope at 4 different extinction/emission wavelengths. Within each TMA 
spot, the area of tumor was distinguished from stromal and necrotic areas by 
creating a tumor specific mask from the anti-CK protein, which was visualized 
from Alexafluor 555 signal. The DAPI image was then used to differentiate 
between the cytoplasmic and nuclear staining within the tumor mask. The pixel 
intensity of the RhoC protein/antibody complex was determined from the AF488 
signal, and finally, the fluorescence pixel intensity of the ALDH1 protein/antibody 












This chapter represents a ―manuscript in progress‖ and will be submitted for 
publication under the title ―RhoC determines the metastatic potential and affects 
the abundance of breast cancer stem cells‖ by Devin T. Rosenthal, Jie Zhang, 
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p38γ regulates breast cancer cell motility and metastasis through 




Understanding the molecular alterations that confer metastatic properties, such 
as increased motility, to otherwise benign breast cells is essential to controlling 
breast cancer and increasing patient survival. We show for the first time that 
p38γ MAPK regulates cell motility and metastasis of aggressive breast cancer 
cells and is associated with the basal breast cancer subtype. p38γ elicits its 
effects on cell motility by affecting expression of another metastasis-associated 
protein, RhoC, through a novel mode of regulation: modulation of RhoC 
ubiquitination. We uncover a mechanistic sequence of events whereby p38γ 
knockdown results in increased RhoC ubiquitination and a subsequent decrease 
in RhoC protein expression, as mediated by lysosomal degradation, ultimately 
resulting in decreased cell motility. The p38γ-RhoC relationship persists across 
multiple cell lines and in clinical breast cancer specimens. We find that p38γ has 
important clinical relevance, as high p38γ expression is associated with lower 
overall survival of breast cancer patients. The data presented here 1) provides a 
detailed characterization of how p38γ contributes to breast cancer progression,
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2) identifies a novel mechanism for regulating RhoC expression, and 3) 
nominates p38γ as an important therapeutic target. 
 
Introduction 
Breast cancer presents as a hyperproliferative disease of mammary epithelial 
cells, which can grow uncontrollably for years yet remain confined within 
mammary ducts or lobules. If diagnosed at this early stage the disease responds 
well to therapeutic intervention (100). Breast cancer becomes much more severe 
once the cancer cells invade out of the mammary ducts and metastasize to vital 
organs. Understanding the molecular alterations that confer metastatic 
properties, such as motility and invasion, to otherwise benign cells is essential to 
controlling the disease and significantly improving patient survival. 
 
p38 MAPK is a serine/threonine kinase responsible for integrating extracellular 
stimuli and translating them into cellular responses by phosphorylating a network 
of downstream effector proteins (57). The p38 arm of the MAPK pathway is 
effected by four closely related isoforms: p38 α, β, γ and δ. Despite their 
sequence similarity and shared upstream kinases, the p38 isoforms can have 
unrelated, and even antagonistic, roles in development and disease (59-63). 
 
p38γ (also referred to as MAPK12, ERK6, or SAPK3) is expressed predominantly 
in muscle tissue where it promotes myoblast differentiation into myotubes (71-
74). p38γ mRNA is overexpressed in several types of cancer (78, 79) and helps 
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increase Ras-induced cancer invasion (81, 82). Viewing the function of p38γ 
through the perspective of its developmental role led us to hypothesize that p38γ 
is involved in enabling mesenchymal-like behavior in breast cancer cells by 
controlling their motility properties. 
 
Using p38γ-specific small hairpin RNA (shRNA), siRNA, and a dominant negative 
construct we reveal that p38γ is a crucial mediator of cellular motility and 
metastasis of aggressive breast cancer cells. p38γ elicits its effects at least in 
part through RhoC GTPase by affecting RhoC ubiquitination and degradation – a 
mechanism of regulation never before observed for RhoC. p38γ and RhoC 
expression are highly correlated in clinical breast cancer samples, and re-
expressing RhoC restores motility to p38γ knockdown cells. Clinically, high p38γ 
expression in patient tissues is associated with the basal breast cancer subtype 
and confers a worse prognosis. The data presented here establish for the first 
time that p38γ is a metastasis-promoting gene responsible for enabling motility 
and metastasis of aggressive breast cancer cells through modulation of RhoC. 
 
Results 
p38γ phosphorylation is elevated in an aggressive breast cancer cell line 
p38 is activated by dual phosphorylation on the Thr and Tyr residues of the 
conserved TGY motif (60, 101). To assess whether p38γ is functionally relevant 
in aggressive breast cancer, we assayed the levels of phospho-p38γ in a 
representative and widely used aggressive breast cancer cell line, MDA-MB-231 
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(―231 cells‖). Compared to the non-tumorigenic mammary epithelial cell line 
MCF-10A, 231 cells have increased levels of phosphorylated p38γ despite 
similar levels of total p38γ (Figure 3.1A).  
 
To investigate the role of p38γ on the metastatic phenotypic features of 231 cells 
we used small hairpin RNA (―shRNA‖) to stably knock down p38γ expression 
(Figure 3.1B). Importantly, the shRNA did not affect expression of the other three 
p38 isoforms (data not shown). Since there is no p38γ-specific pharmacologic 
inhibitor we overexpressed dominant negative p38γ (102) (―DNp38γ‖) in MDA-
MB-231 cells as an additional method to inhibit p38γ (See Supplementary 
Methods and Figure 3.S1). 
 
Cell shape and cytoskeletal architecture are altered by p38γ knockdown 
Immediately apparent in the p38γ knockdown cells (―shp38γ cells‖) was a change 
in cell morphology compared to scrambled control cells (―scrambled cells‖). While 
scrambled cells exhibited the elongated morphology characteristic of 231 cells 
and mesenchymal cells in general, shp38γ cells adopted a more rounded cell 
shape (Figure 3.1C), as did DNp38γ cells (Figure 3.S1C). This change was 
shown quantitatively by measuring the cells‘ aspect ratio (see Methods). As 
depicted in Figure 3.1C (right), shp38γ cells are significantly less elongated than 
their scrambled counterparts (aspect ratio of scrambled = 4.27, shp38γ = 0.81, p-




Extending from this observation we asked whether the actin cytoskeleton was 
modified in shp38γ cells. Using immunofluorescent confocal microscopy we 
observed that shp38γ cells have a strikingly disorganized actin cytoskeleton 
(Figure 3.1D), as do DNp38γ cells (Figure 3.S1E). Scrambled cells form long 
actin stress fibers traversing the length of the cell characteristic of mesenchymal-
like cells, well-aligned along the long axis (Figure 3.1D, left). shp38γ cells still 
have thick actin bundles resembling the stress fibers in the scrambled cells, but 
with a bimodal distribution and are primarily confined to the leading edge (Figure 
3.1D, right). This cluster of actin bundles forms the lamellipodia-like structure 
present in shp38γ cells (Figures 3.1C-D) but shows little similarity to classic 
lamellipodia cytoskeletal architecture, which normally consists of thin branched 
actin filaments forming a protrusive meshwork (103). 
 
p38γ knockdown dramatically alters cell motility 
Elongated cell shape is one factor that can delineate the mode of motility used by 
a cell and distinguish metastatic from non-metastatic cancer cells in vitro (104, 
105). To determine whether the rounded shape and modified cytoskeletal 
architecture of the shp38γ cells indicated a change in metastatic properties we 
first analyzed cell motility using time lapse microscopy.  
 
p38γ knockdown had a profound effect on the quality of cell motility (Figure 3.2A) 
and on the velocity (Figure 3.2B). Scrambled control cells moved in a 
mesenchymal-like manner, consistent with their appearance and cytoskeletal 
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structure, forming long pseudopodial projections that adhered to the cell 
substrate and allowed the cells to ―pull‖ themselves along in alternating cycles of 
protrusion and contraction (Figure 3.2A, top, and Video 1). shp38γ cells, 
however, appeared to have difficulty polarizing and were unable to form long 
pseudopodia (Figure 3.2A, bottom, and Video 1). The cells moved inefficiently 
using a broad lamellipodia-like structure and exhibited detachment anomalies at 
the rear of the cell. 
 
To quantitatively assess the effect of p38γ knockdown on cell motility, cell tracks 
were generated and the resulting trajectories were measured (Figure 3.2B). 
shp38γ cells were less motile than scrambled control cells, as evidenced by 
significantly reduced cell speed (Figure 3.2B). Taken together, these data show 
that p38γ knockdown affects cell shape and inhibits efficient mesenchymal-like 
motion in a qualitative and quantitative manner. 
 
p38γ knockdown impairs the in vitro metastatic behavior of 231 cells 
Based on the reduced motility of the shp38γ cells we asked whether p38γ also 
affects other aspects of breast cancer metastasis. A crucial step in the metastatic 
process is invasion through the basement membrane that separates the 
epithelial ductal layers from the connective tissue parenchyma. When subjected 
to a Matrigel invasion assay shp38γ cells exhibited a 40% reduction in invasion 
compared to scrambled cells (Figure 3.2C), indicating that p38γ functions in this 




To replicate in vitro the possible behavior in vivo we employed a three-
dimensional cell culture system capable of promoting normal development of 
breast epithelial cells as well as illustrating the specific tumorigenic and 
metastatic properties of breast cancer cells (88, 89). Scrambled cells grown in 3D 
exhibited a stellate morphology characteristic of metastatic cells (Figure 3.2D, 
top) (89, 90). The cells were not organized into cohesive structures and invaded 
away from the central mass through the surrounding extracellular matrix. In 
contrast, shp38γ and DNp38γ cells formed non-invasive round acinar-like 
structures (Figure 3.2D, bottom, and Figure 3.S1D). Interestingly, shp38γ cells 
still did not form proper acini, as shown by an inability to apoptotically clear the 
lumen (Figure 3.2D, right). Taken together, these results strongly support a role 
for p38γ in the early steps of breast cancer metastasis. 
 
Expression of the cytoskeletal remodeler and metastatic oncogene RhoC is 
decreased in shp38γ cells 
The Rho-family GTPases (Rac, Rho, and cdc42) are the classic regulators of 
actin cytoskeletal dynamics driving cell motility (106). Based on the actin 
cytoskeletal changes and motility defects we observed we hypothesized that 
p38γ knockdown affected members of the Rho GTPase family. Interestingly, we 
found that RhoC GTPase protein levels were strongly downregulated in both 
shp38γ and DNp38γ cells (Figure 3.3A and S1F) with no change in the close 
homolog RhoA (data not shown). Surprisingly, RhoC mRNA levels were not 
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affected by p38γ knockdown (Figure 3.3B), suggesting that p38γ influences 
RhoC expression at the translational or post-translational level. 
 
p38γ knockdown leads to increased RhoC ubiquitination and degradation 
To determine whether p38γ affects RhoC expression at the translational or post-
translational level we treated scrambled and shp38γ cells with the translation 
inhibitor cycloheximide and observed the effect on protein expression. 
Cycloheximide treatment caused a rapid decrease in RhoC protein levels in 
shp38γ cells with no corresponding decrease in scrambled cells (Figure 3.3C), 
indicating that RhoC protein is less stable in shp38γ cells. 
 
Upon observing this change in RhoC protein stability we asked whether RhoC 
was ubiquitinated in shp38γ cells—a common marker of proteins slated for 
degradation. When we assayed RhoC ubiquitination we found that levels of 
ubiquitinated RhoC were increased in shp38γ cells compared to scrambled cells 
(Figure 3.3D).  
 
To elucidate the mechanism by which RhoC is degraded we treated cells with 
either proteasome inhibitors (MG132 or lactacystin) or lysosome inhibitors 
(ammonium chloride or chloroquine) and observed the effect on RhoC protein 
levels. Inhibiting the lysosome led to an increase in RhoC protein (Figure 3.3E) 
whereas proteasome inhibitors had no effect on RhoC expression (data not 
shown), indicating that ubiquitinated RhoC is degraded by the lysosome. Taken 
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together, these data support the conclusion that p38γ affects RhoC expression 
by mediating RhoC protein stability through regulation of RhoC ubiquitination and 
lysosomal degradation. 
 
Rescuing RhoC expression restores motility to shp38γ cells 
Based on the established role that RhoC plays in cell motility (47) we 
hypothesized that decreased RhoC expression in shp38γ cells may directly 
contribute to the impaired motility of shp38γ cells. To test this hypothesis we 
stably transfected either RhoC or a constitutively active form of RhoC (RhoC 
G14V) into shp38γ cells to see if this could restore motility to these cells (Figure 
3.4A). It is important to note that we selected two clones for each form of RhoC—
one low expressing and one high expressing—to ensure that any effects we 
observed were not simply due to unrealistically high expression of the transfected 
gene.  
 
When we observed the motility of the transfected clones we found that re-
expressing RhoC significantly increased motility of the shp38γ cells to levels 
comparable to scrambled control cells (Figure 3.4B). Interestingly, the increase in 
cell speed seemed to have a near-linear relationship with RhoC 
expression/activity. Combined with our previous observations, these data 
establish a novel mechanistic link whereby p38γ directs cell motility through 




p38γ and RhoC expression are highly correlated in human breast cancer 
tissues 
We next asked whether the relationship between p38γ and RhoC persists in 
human breast cancer tissues. To address this question we assayed expression 
of p38γ and RhoC using AQUA of immunofluorescence signals for each marker 
in cytokeratin-positive cells from a breast cancer tissue microarray. Analysis of 
177 breast cancer specimens revealed a strong positive correlation between 
p38γ and RhoC expression (Figure 3.4C). Taken together with our in vitro 
results, these data strongly support a relationship between p38γ and RhoC in 
breast cancer, one that likely involves p38γ regulation of RhoC expression. 
 
p38γ affects the metastatic properties of other aggressive breast cancer 
cell lines 
Because p38γ specifically alters the actomyosin contractile motility of MDA-MB-
231 cells by affecting RhoC expression, we asked whether p38γ plays a similar 
role in other mesenchymal-like breast cancer cell lines. To address this question 
we used two additional widely studied breast cancer cell lines – Hs578t and 
BT549 – both of which have increased levels of phosphorylated p38γ compared 
to both MCF-10A and HME non-tumorigenic mammary epithelial cells (Figure 
3.5A). Using siRNA, we transiently knocked down p38γ expression in these two 





siRNA knockdown of p38γ (―sip38γ‖) dramatically affected the actin cytoskeletal 
architecture and cell shape of both cell lines in a manner consistent with 231 
shp38γ cells (Figure 3.5C-D). Accordingly, sip38γ cells moved significantly less 
than scrambled cells (Figure 3.5E-F). p38γ knockdown in these cell lines also 
reduced RhoC expression (Figure 3.5G). Taken together, these results support 
our conclusion that p38γ plays a crucial role in driving the motility of aggressive 
breast cancer cells by modulating RhoC expression. 
 
p38γ is related to the basal breast cancer subtype  
Having discovered that p38γ is associated with mesenchymal-like cell motility 
and is overactivated in three basal breast cancer cell lines, we hypothesized that 
p38γ is associated with the basal breast cancer subtype. To test this hypothesis 
we assayed p38γ expression in 43 breast cancer patient samples which were 
previously analyzed for molecular subtype by PAM50 (107). We found that the 
basal subtype is significantly enriched in the top quartile of p38γ-expressing 
tumors (p = 0.018, Figure 3.6A), whereas none of the other subtypes examined 
showed significant association with p38γ expression (data not shown).  Taken 
together with our in vitro data on p38γ function in mesenchymal-like cell 
behavior, this clinical data strongly supports an association between high p38γ 
expression and the aggressive basal breast cancer subtype. 
 
p38γ promotes breast cancer metastasis in vivo and is clinically associated 
with lower overall patient survival 
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Based on our in vitro observations we hypothesized that p38γ knockdown would 
reduce the metastatic potential of MDA-MB-231 breast cancer cells in vivo. To 
test this hypothesis we orthotopically xenografted athymic nude mice with 231 
scrambled and shp38γ cells and allowed tumors to grow for 14 weeks, at which 
point we resected the tumors and analyzed the lymphatics for signs of tumor cell 
metastasis. Two-thirds of the mice injected with scrambled cells presented with 
lymphatic invasion and metastasis, compared to just over one-tenth of shp38γ-
injected mice (Figure 3.6B-C). This in vivo data, combined with the extensive 
body of in vitro data presented here, strongly implicate p38γ as a metastatic 
oncogene that exerts its effects, at least in part, by driving cell motility through 
regulation of RhoC. 
 
As a final means of determining the clinical relevance of p38γ expression we 
assayed p38γ expression in a cohort of 118 breast cancer cases containing 
patient survival data. Using the upper quartile of p38γ expression as a cutoff 
reveals a significant association between high p38γ expression and lower overall 
patient survival (p = 0.013, Figure 3.6D). This clinical data supports our in vitro 
and in vivo findings that p38γ is an important mediator of breast cancer cell 
aggressiveness, and establishes that p38γ expression has important implications 








As the breast is a non-vital organ, primary tumor burden is very rarely the direct 
cause of cancer-specific mortality. Instead, metastasis of cells from the primary 
tumor to vital organs results in patient death. Here we demonstrate that p38γ is a 
novel metastasis-modulating oncogene, deduce a mechanistic link between 
p38γ, its effect on RhoC, and the shp38γ phenotype, and reveal that this link has 
clinical relevance. 
 
The importance of the p38 MAPK pathway in cancer has been appreciated (59, 
108), but very diverse and sometimes contradictory roles have been described 
for p38 in cancer (79). In agreement with other recent findings (82, 109) we show 
that at least some of the heterogeneity of p38 functions may be attributed to the 
distinct contributions of specific p38 isoforms. Since the p38 MAPK pathway is a 
ubiquitously utilized stress-responsive pathway, it logically follows that 
metastasizing cancer cells, which encounter an ever-changing milieu of cellular 
stresses, may gain survival advantages under these stressed conditions upon 
modulation of the appropriate p38 MAPK isoforms; thus, dissecting the 
contributions of each p38 isoform would allow more precise targeting of specific 
subsets of cancer.  
 
In support of this assertion we found that p38γ is more frequently associated with 
the basal breast cancer subtype – the most lethal molecular breast cancer 
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subtype. p38γ is thus an especially promising drug target as, in addition to the 
data presented here, it is a kinase, has restricted tissue expression (71, 73, 74), 
and lacks a phenotype when knocked out in mice (68)—possibly indicating that 
its inhibition may offer a differential detrimental effect on tumor versus normal 
cells. 
 
Similarly to mediators of normal mesenchymal differentiation, such as twist and 
snail, which have been shown to also be important drivers of cancer progression 
(15, 110), so is the case for p38γ. p38γ functions in muscle cell differentiation, 
and thus it is consistent that it plays a role in aggressive, mesenchymal-like 
breast cancer cells. Interestingly, p38γ appears to exert its effects independent of 
classical cell differentiation markers, as p38γ knockdown does not alter 
expression of epithelial-to-mesenchymal transition markers such as vimentin or 
E-cadherin (data not shown) despite significantly reverting the mesenchymal-like 
phenotype of aggressive breast cancer cells. Although there are many other 
genes that have been shown to drive metastatic transition (111), based on the 
data presented here and in another recent publication (112) we propose that 
p38γ serves as a crucial regulator of the major cytoskeletal changes necessary 
for the switch to rapid, mesenchymal-like cell motility—independent of 
differentiation status—at least in part through its modulation of the major 




RhoC is involved in stress fiber formation and actomyosin contraction (51, 113)—
both of which are perturbed by p38γ knockdown—and has previously been linked 
to the p38 MAPK pathway (56). RhoC also promotes metastasis in several types 
of cancer, including breast (51-54), and plays a larger role in stress fiber 
formation and contraction than RhoA (49); thus we postulated that changes in 
RhoC expression influence the shp38γ phenotype. In support of this hypothesis 
we found that re-expressing RhoC alone was sufficient to restore motility to 
shp38γ cells—a surprising feat, given the multitude of proteins involved in cell 
motility (39, 40), which highlights the importance of RhoC in p38γ-mediated cell 
motility. Further supporting the link between p38γ and RhoC is our finding that 
expression of the two proteins is concurrently altered in clinical breast cancer 
specimens (Figure 3.4A), suggesting that the p38γ-RhoC axis may be 
functionally significant—and a potentially druggable target—in the clinic. 
 
In our investigation of the interaction between p38γ and RhoC we discovered that 
p38γ regulates RhoC expression by preventing RhoC ubiquitination and 
subsequent lysosomal degradation. Ubiquitination and protein degradation have 
recently emerged as important mechanisms for regulating Rho GTPase 
expression (114), however this is the first demonstration of modulating RhoC 
ubiquitination as a relatively fast mechanism that can regulate RhoC action within 
a time domain relevant to cell motion. Further research into the specific proteins 
and mechanisms regulating ubiquitination of RhoC and other Rho GTPases 
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should have significant impact on our understanding how cell motility and 
metastasis are regulated.  
 
We found that RhoC was degraded by the lysosome, rather than through the 
canonical proteasome degradation pathway. Although proteasomal degradation 
is by far the dominant mechanism for protein degradation under stress-free 
conditions, interestingly lysosomal degradation accounts for nearly 40% of 
protein degradation in muscle cells.  
 
Research such as this may also be readily applicable to the clinic, specifically in 
the case of aggressive cancer subtypes—most notably inflammatory breast 
cancer (IBC)—which may rely on RhoC expression for metastasis. Targeting the 
proteins that regulate RhoC expression, in addition to or in place of targeting 
RhoC directly, should impact diseases such as IBC, which currently lacks 
effective treatments. 
 
Materials and Methods 
Reagents 
shRNA was purchased from Open Biosystems through the University of Michigan 
Life Science Institute High Throughput Screening Core. A dominant negative 
p38γ plasmid (102) (Addgene plasmid 20354) was a kind gift from Roger Davis. 
FITC-labeled siRNA, cycloheximide, chloroquine, and ammonium chloride were 
purchased from Sigma Aldrich. For western blotting the following antibodies were 
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used: rabbit anti-p38α, anti-p38β, anti-p38γ, anti-p38δ, anti-RhoC, and mouse 
anti-phospho-p38 (Cell Signaling); goat anti-actin and mouse anti-ubiquitin 
(Santa Cruz Biotechnology); and mouse anti-hemagglutinin (Covance). 
 
Cell Lines 
Untransfected cell lines were cultured in RPMI 1640 (MDA-MB-231, BT549) or 
DMEM (Hs578t) supplemented with 10% fetal bovine serum, or DMEM/F12 
(MCF-10A) supplemented with 10% horse serum. Selection media for shRNA-
transfected cells consisted of standard cell line media containing 1μg/ml 
puromycin. MDA-MB-231 stably transfected with both shRNA and RhoC/RhoC 
G14V were cultured in standard cell line media containing 1μg/ml puromycin and 




2 μg of pGIPZ plasmid containing either scrambled or p38γ-specific shRNA were 
nucleofected into 50-70% confluent MDA-MB-231 cells according to the 
manufacturer‘s protocol (Lonza). Nucleofected cells were selected in puromycin 
and further isolated by FACS sorting for GFP. The same nucleofection process 
was used for RhoC/G14V plasmids (cDNA.org). Nucleofected cells were selected 




3 nM siRNA was transfected into 50-70% confluent BT549 and Hs578t cells 
using Oligofectamine (Invitrogen) according to the manufacturer‘s protocol. Gene 
expression and cell behavior were observed 48 hours post transfection. 
 
Phospho-p38γ Immunoprecipitation/Western Blot 
Protein was extracted from 70% confluent cells with RIPA buffer. Total protein 
extracts were incubated with primary antibody (anti-p38γ or anti-phospho-p38) 
overnight at 4°C. The following morning protein-antibody complexes were 
captured by incubation with protein A/G beads (Santa Cruz Biotechnology). 
Immunoprecipitates were run on an SDS-PAGE gel, transferred to a 
nitrocellulose membrane, and probed with the appropriate reciprocal antibody 
(anti-p38γ or anti-phospho-p38). 
 
Aspect Ratio Calculation 
Images were acquired at room temperature using a Leica DM IRB microscope 
equipped with a Leica 20x/0.4 NA objective and Hamamatsu ORCA-03G camera 
with Metamorph software. Aspect ratio calculations were performed using 
ImageJ (97). The aspect ratio formula is length over width – length defined as the 
greatest distance perpendicular to the cell‘s leading edge (as determined by 
cytoskeletal architecture), and width as the longest distance between points 
measured perpendicular to the axis defining the length. Therefore a cell that is 
elongated in the direction of motion will have an aspect ratio greater than 1, while 




3D Cell Culture 
Cells were cultured as described by Lee et al. (89). Briefly, 4-well chamber slides 
(Lab-Tek) were coated with growth factor-reduced Matrigel (BD Biosciences). 
Cells were plated at a density of 2.1 x 104 cells/cm2 in cell media containing 4% 
Matrigel and cultured for 4 days. The same microscope and imaging conditions 
were used as above. 
 
Time-Lapse Microscopy 
DIC time-lapse videos were captured at 37°C using a Deltavision RT Live Cell 
Imaging System equipped with UPlanApo 20x/0.7 NA and 40x/1.2 NA lenses at 
the University of Michigan Microscopy and Image Analysis Lab. Images were 
acquired using SoftWoRx 3.5.1 software. Cell motility videos were enhanced and 
analyzed using Imaris (Bitplane Scientific Software), from which the average 
speed of each cell line was calculated in μm/hour. 
 
Actin Immunocytochemistry 
50-70% confluent cells were fixed with 4% paraformaldehyde. Cells were then 
incubated in 1:50 AF568-phalloidin in PBS (Invitrogen) for 10 minutes, rinsed 
once in PBS for 5 minutes, and mounted with Prolong Gold anti-fade with DAPI. 
Images were acquired at room temperature using a Zeiss LSM 510 Meta laser-
scanning microscope equipped with a C-Apochr 40x/1.2 NA and LSM 510 
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software. Each channel was imaged sequentially using multitrack recording 
before merging. Enhancements were performed using Photoshop (CS2; Adobe). 
 
In situ detection and quantification of protein expression 
Tumors and Patients 
Fresh and formalin-fixed, paraffin-embedded tissue blocks (FFPE) of Breast 
Cancer were obtained from the files of the Department of Pathology, University of 
Michigan Medical Center, Ann Arbor, MI. IRB approval was obtained and the 
diagnosis was confirmed by morphology. After pathological review, a tissue 
microarray was constructed from the most representative area using the 
methodology of Nocito et al. (98). Survival data was obtained from the Cancer 
Registry of The University of Michigan. 
Immunohistochemical Staining and AQUA analysis. 
Triple immunofluorescence staining was performed as previously described (99) 
and the AQUA system (HistoRx, New Haven, Connecticut) was used for the 
automated image acquisition and analysis. The detailed staining and imaging 
procedure can be found in the Supplemental Methods.  
 
Orthotopic Xenografts and Lymphatic Metastasis Analysis 
All mouse work was performed in accordance with the University‘s standards for 
animal use. 231 scrambled and shp38γ cells were diluted 1:1 with Matrigel (BD 
Biosciences) to a final concentration of 3 x 106 cells/ml. Athymic nude mice were 
anesthetized and 1.5 x 105 cells (50 μl) were injected directly into the fourth 
79 
 
mammary gland. Tumors were monitored weekly and mice were euthanized 
once tumor volume approached 2 cm3. Tumors were resected at the time of 
euthanization, fixed in 10% formalin, and were subsequently paraffin embedded. 
Hematoxylin and eaosin-stained tumor sections were scored for lymphatic 
metastasis in a single-blind manner by Dr. J. Erby Wilkinson at the ULAM 
Pathology Core. The number of mice presenting with lymphatic metastases were 
compared using Fisher‘s exact test. Images were captured at room temperature 
using an Olympus BX-51 upright light microscope with Olympus UPlanApo 
10x/0.4 NA and 40x/0.85 NA objectives and an Olympus DP-70 high resolution 
digital camera with DP controller software. 
 
Invasion and Bead Motility 
Invasion (BD Biosciences) and bead motility (Thermo Scientific) assays were 
performed as previously described (56). Growth factor-reduced Matrigel was 
used for invasion assays. Images were taken at room temperature with a Leica 
MXFL III stereo microscope equipped with an Olympus DP-71 digital camera with 
DP controller software.  
 
Statistical analyses 
All p-values were calculated by Student‘s two-tailed t-test unless otherwise 
noted. Expression levels of p38γ and RhoC in TMA samples were compared 
using Spearman‘s rank coefficient. Association between p38γ and breast cancer 
subtype was determined by Fisher‘s exact test. The relationship between p38γ 
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expression and patient survival was calculated by Kaplan Meier analysis, with 






Figure 3.1 – p38γ governs MDA-MB-231 cell shape. (A) Phospho-p38γ levels 
are elevated in the aggressive breast cancer cell line MDA-MB-231 compared to 
non-tumorigenic MCF-10A mammary epithelial cells. (B) shRNA knockdown of 
p38γ in MDA-MB-231 cells. (C) (left) Cell shape difference between scrambled 
and shp38γ cells. (right) Quantification of cell shape difference by aspect ratio 
measurement (length/width) (*p = 7.82 x 10-7, n = 22 cells for scrambled, n = 27 
cells for shp38γ, scale bar = 25 μm). Data are representative of three 
independent experiments and are represented as ± s.e.m. (D) Actin cytoskeleton 
of scrambled and shp38γ cells showing the lengthwise, parallel stress fibers in 
scrambled cells (left) contrasting the bimodal fibers confined to the leading edge 




Figure 3.2 – p38γ knockdown impairs the metastatic properties of MDA-MB-
231 cells. (A) Representative images from time lapse videos (see Video 1) of 
scrambled and shp38γ cells, demonstrating the characteristic mesenchymal-like 
motility of scrambled cells (top) and the non-productive crawling motion of 
shp38γ cells (bottom) (scale bar = 10 μm). (B) (left) Cell tracks from the videos in 
(A). (right) shp38γ cells are significantly slower than scrambled cells and 
accordingly travel less total distance (data not shown) (*p = 3.34 x 10-5, n = 30 
cells per cell line). (C) p38γ knockdown reduces MDA-MB-231 invasion through 
growth factor reduced Matrigel-coated transwell chambers. Representative wells 
are shown on the left, normalized OD readings from three independent 
experiments are represented on the right (*p = 0.022). Graphs in (B) and (C) are 
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represented as ± s.e.m. (D) Three-dimensional Matrigel culture of scrambled and 
shp38γ cells (right image is center slice of confocal stack, all others widefield) 
(left scale bar = 100 μm, right scale bar = 20 μm). All data are representative of 




Figure 3.3 – p38γ affects RhoC expression by mediating RhoC 
ubiquitination and lysosomal degradation. Expression of RhoC GTPase 
protein (A) but not mRNA (B) is significantly reduced by p38γ knockdown. (C) 
Treating cells with the translation inhibitor cycloheximide reveals that RhoC 
protein is less stable in shp38γ cells. (D) RhoC ubiquitination is increased in 
shp38γ cells. (E) RhoC is degraded by the lysosome, as treatment with lysosome 





Figure 3.4 – p38γ and RhoC are functionally related and are co-expressed 
in clinical breast cancer samples. (A) shp38γ cells were stably transfected with 
either HA-tagged RhoC (left) or a constitutively active form of RhoC, RhoC G14V 
(right). Two clones—one high expressing and one low expressing—were 
selected for each construct. (B) The motility of stably transfected clones was 
analyzed by time lapse microscopy. Re-expressing RhoC in shp38γ cells 
significantly increases shp38γ cell speed to levels comparable to scrambled cells 
(*p<0.05). (C) p38γ and RhoC expression were quantified by AQUA from tissue 
microarrays of 177 breast cancer cases. Expression of the two proteins is 





Figure 3.5 – p38γ functions similarly in two additional aggressive breast 
cancer cell lines. (A) Levels of phospho-p38γ are elevated in the aggressive 
breast cancer cell lines MDA-MB-231, Hs578t, and BT549 compared to both 
HME and MCF-10A non-tumorigenic mammary epithelial cells. Graph shows 
IP/input (phospho-p38γ/total p38γ) quantification of a representative western blot. 
(B) Transient siRNA knockdown of p38γ in BT549 and Hs578t cells. The siRNA 
did not affect the other p38 isoforms (data not shown). (C-D) The actin 
cytoskeleton and cell shape of sip38γ BT549 (C) and Hs578t (D) cells are altered 
in a manner similar to 231 shp38γ cells (scale bar = 25 μm). Data are 
representative of three independent experiments. (E-F) p38γ knockdown reduces 
cell motility significantly, as measured by a bead motility assay in BT549 (E) and 
Hs578t (F) cells (For two BT549 siRNAs: *p = 0.0428, **p = 1.64 x 10-5; for two 
Hs578t siRNAs: *p = 0.0001, **p = 0.0012. All data are represented as the 
average of three independent experiments ± s.e.m.). (G) RhoC expression is 




Figure 3.6 – p38γ is associated with the basal breast cancer subtype and 
affects metastasis and patient survival. (A) The basal breast cancer subtype 
is enriched in the top quartile of p38γ-expressing patient samples (―High p38γ‖) 
(p = 0.018).  (B) Quantification of lymph node metastasis of orthotopically 
xenografted 231 scrambled and shp38γ cells. Scrambled cells had a significantly 
higher incidence of metastasis into lymph nodes in both the ipsilateral and 
contralateral mammary glands (p = 0.047), as measured by Fisher‘s exact test. 
(C) Representative tissues of 231 scrambled cells invading the ipsilateral lymph 
node (left) and a metastatic cluster in the contralateral respective mammary 
gland (right). The intact lymph node capsule is indicated by the arrowhead while 
invading scrambled cells are marked by the arrow and magnified in the inset (all 
scale bars = 100 μm). (D) High p38γ expression is associated with lower overall 





Supplemental Materials and Methods 
 
Generation of dominant negative p38γ MDA-MB-231 cells 
Selection media for cells transfected with dominant negative p38γ consisted of 
standard cell media containing 350μg/ml G418. For dominant negative p38γ 
cells, 1 μg of pcDNA-FLAG-p38γ agf was transfected into 50-70% confluent 
MDA-MB-231 cells using Genejammer transfection reagent (Stratagene) 
according to the manufacturer‘s instructions. Transfected cells were selected in 
G418 and positive clones were isolated. 
 
Use of a dominant negative p38γ construct to validate shRNA results 
As there is no p38γ-specific pharmacologic inhibitor we instead used a dominant 
negative p38γ construct (102) to validate our shRNA results. The dominant 
negative p38γ (―DNp38γ‖) has the Thr and Tyr residues of the TGY 
phosphorylation motif mutated to non-phosphorylatable Ala and Phe, and will 
thereby competitively inhibit endogenous p38γ binding to its activating kinases 
(102). However, p38γ shares its upstream kinases, MKK3 and MKK6, with the 
other p38 isoforms – therefore DNp38γ likely interferes to an extent with 
signaling through the other isoforms. To help minimize these off-target effects we 
selected clones with low levels of DNp38γ that were still able to reduce p38γ 
phosphorylation (Figure 3.S1A). 
Immunohistochemical Staining and AQUA analysis 
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Briefly, after deparaffinization and rehydration, TMA slides were subjected to 
microwave epitope retrieval in 7.5 mM sodium citrate buffer, pH6. After rinsing 
several times in 10 mM Tris HCL buffer, pH 8 containing 0.154 M NaCl (TBS), 
endogenous peroxidase activity was blocked with 2.5% (v/v) H2O2 in methanol 
for 30 minutes. Non-specific binding of the antibodies was extinguished by 30 
minute incubation with ‘Background Sniper” (BioCare Medical, Concord, CA). 
The TMA slide was then incubated with the tumor-specific antibody, cytokeratin 
(AbD Serotec, Raleigh, NC, Mouse monoclonal antibody, MCA144HT, 1:50) 
overnight at 4C. The slides ere then washed with TBST twice for 5 minutes and 
then once with TBS for 5 minutes. The slides were then incubated with the 
antibodies to RhoC (chicken IgY polyclonal antibody, 1:1000, described in (115)) 
and p38  (Abgent, rabbit polyclonal antibody, AP7224c, 1:50) for 60 minutes at 
room temperature. Slides were then washed as described above and incubated 
with a combination of goat anti mouse IgG conjugated to AF555 (Molecular 
probes, Carpinteria, CA, A21424, 1:200) and goat anti chicken IgY conjugated to 
AF488 (Molecular probes, Carpinteria, CA, A11039, 1:200) in goat anti rabbit 
Envision+ (DAKO, Carpinteria, CA) for 60 minutes at room temperature in a dark 
humidity tray. The slides were then washed as described above and the target 
image was developed by a CSA reaction of Cy5 labeled tyramide (PerkinElmer, 
Waltham, MA, 1:50). The slides were washed with 3 changes of TBS and stained 
with the DNA staining dye 4’,6-diaminodo-2-phenylindole (DAPI) in a non-fading 
mounting media (ProLong Gold, Molecular probes, Carpinteria, CA). The slides 




For AQUA, images of each TMA core were captured with an Olympus BX51 
microscope at 4 different extinction/emission wavelengths. Within each TMA 
spot, the area of tumor was distinguished from stromal and necrotic areas by 
creating a tumor specific mask from the anti-CK protein, which was visualized 
from Alexafluor 555 signal. The DAPI image was then used to differentiate 
between the cytoplasmic and nuclear staining within the tumor mask. The pixel 
intensity of the RhoC protein/antibody complex was determined from the AF488 
signal, and finally, the fluorescence pixel intensity of the p38  protein/antibody 





Figure 3.S1 – Creation and analysis of dominant negative p38γ clones. (A) 
Western blot showing FLAG-DNp38γ expression in stably transfected clones. (B) 
IP/western blot of phospho-p38γ levels in DNp38γ clones, indicating that p38γ 
phosphorylation is decreased by overexpression of DNp38γ. (C) Aspect ratio of 
DNp38γ clones is decreased compared to vector control cells (*p<0.05). Data are 
represented as ± s.e.m. (D) Three-dimensional Matrigel culture of vector control 
and DNp38γ cells, which show the same stellate (vector) and non-invasive 
(DNp38γ) phenotypes as scrambled and shp38γ cells, respectively (scale bar = 
100 μm). (E) Actin cytoskeleton of vector and DNp38γ cells, showing a 
reorganization of the cytoskeleton and rounded cell shape (scale bar = 20 μm). 
(F) Expression of the cytoskeletal regulator and metastatic oncogene RhoC in 
vector and DNp38γ cells. 
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Video 1 – MDA-MB-231 shp38γ cells have impaired motility. MDA-MB-231 
cells stably transfected with either a scrambled control shRNA (left) or shRNA 
targeting p38γ (right) were imaged by time lapse DIC microscopy (Deltavision 




































This chapter represents a ―manuscript in submission‖ currently in review at 
Cancer Research under the title ―p38γ drives breast cancer cell motility and 
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Computational mechanical modeling reveals the role of p38γ in shaping the 




Breast cancer lethality is primarily due to metastasis to distant vital organs. In the 
multi-step process of dissemination cancer cells acquire pro-metastatic 
properties, such as rapid motility. Understanding both the molecular alterations 
and associated physical behaviors that confer effective and fast locomotion to 
otherwise slow-moving breast cancer cells is therefore paramount to uncovering 
a potentially modifiable determinant of metastases. We show for the first time 
that p38γ MAPK controls cell motility specifically by regulating cytoskeletal 
morphology. Using a computational mechanical model, which is based on the 
finite element method, we demonstrate that p38γ-mediated cytoskeletal changes 
are sufficient to control cell motility. The model predicted novel dynamics of 
leading edge actin protrusions, which were verified experimentally, and which 
proved to be closely related to cell shape and cytoskeletal morphology.  
 
Major findings 
By combining cell biology and computational mechanical modeling, we establish 
p38γ as a metastatic oncogene responsible for controlling breast cancer cell 
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motility. Additionally, we demonstrate how p38γ specifically exerts this effect: we 
show that the dynamics of leading edge actin protrusion and trailing edge 
retraction by stress fibers determine the type of cell motility and locomotion, but 
they cannot act independently of cell shape and cytoskeletal architecture. We 
further deduce that p38γ is the key signaling link between cell shape, cytoskeletal 
structure, and the type of motion the cell exhibits. 
 
Introduction 
Cell motility involves the precise coordination of a broad array of signaling 
pathways, physical cues, and other environmental stimuli in order to generate 
coordinated mechanical forces that result in effective locomotion. Cells use 
different forms of motion; e.g., lamellipodial vs. filopodial; the latter commonly 
associated with mesenchymal-like cells. A mesenchymal cell makes linear 
progress in a given direction by coordinating (a) cell polarization by stress fiber 
formation in the direction of motion, (b) protrusion of the actin cytoskeleton at the 
cell‘s leading edge, (c) formation and adherence of focal adhesions at the leading 
edge, and (d) contraction of stress fibers by actomyosin-driven contractility, 
which causes retraction of the trailing edge by detachment and dissolution of 
focal adhesions there. These processes are triggered and sequentially regulated 
through an array of rapidly cycling  signaling molecules, the most widely studied 
of them being the Rho GTPases: cdc42, Rac and Rho proteins, whose 
localization and activation are associated with the formation of filopodia, 
lamellipodia and stress fibers, respectively (116). The principles of mechanics 
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govern how the actions of these cytoskeletal structures produce motility and 
whole cell locomotion. The ability to properly shift from sessile to motile by 
exploiting mechanics is a hallmark of many developmental processes and is 
harnessed at the cellular and tissue levels in disease states such as cancer 
(117).  
 
Cancer progression is broadly characterized by a shift from largely stationary, 
proliferative cells in the primary tumor to motile and invasive metastatic cells. In 
breast cancer and other epithelial cancers, this phenomenon is generally 
attributed to cells undergoing an epithelial-to-mesenchymal transition (EMT). 
During EMT cells shift from being coherent sheet-like epithelial cells to 
dynamically contractile, motile, mesenchymal-like cells. This change is evident 
even in culture in aggressive breast cancer cell lines such as MDA-MB-231, 
where cells appear fibroblast-like and move rapidly using a dynamic, contractility-
based form of motility. 
 
Coordination of motility to achieve effective locomotion requires the integration of 
inputs from broad-ranging environmental cues and stresses, and their translation 
into intracellular signaling for the proper orientation and turnover of the actin 
cytoskeleton, among other events. Although cytoskeletal remodeling that leads to 
motility generally runs through the Rho GTPase pathway (116), other upstream 
signaling molecules are responsible for translating extracellular stimuli into 
intracellular responses. Understanding the specific genetic alterations that lead to 
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a given motility phenotype is intrinsically difficult, as it is often a combination of 
heterogeneous genetic changes that contribute to a phenotype. Additionally, 
many signaling modifications—be they natural, or as a result of therapeutic 
intervention—are often compensated for by other signaling pathways or 
mechanisms, as pathways are not linear but rather interconnected information 
networks with extensive cross-talk. 
 
Such a complex system can, in principle, be understood by using mathematics; 
in this case we adopted computational mechanical modeling as the tool to 
accomplish this. A full treatment of cell motility and locomotion as a complex 
system would include detailed models for sensing external stimuli, the signaling 
cascades that are generated, as well as the mechanical events of cytoskeletal 
remodeling and cell locomotion. Such an undertaking, however, presents 
daunting challenges in theory and computation, and indeed may not be entirely 
necessary: In this communication we have adopted a reduced representation in 
which only the mechanical events are modeled, while the external stimuli and cell 
signaling are taken as given. With this relatively simplified approach that 
nonetheless captures the crucial details of the internal mechanics of the cell, we 
are able to elucidate the central mechanical aspects of how cell shape, 
cytoskeletal morphology and actin dynamics give rise to motility, and ultimately to 




We have recently identified p38γ as a crucial regulator of breast cancer cell 
motility and metastasis (simultaneous submission) (118). Our findings indicate 
that a hallmark feature of modulating p38γ expression is the alteration of 
cytoskeletal orientation and architecture. Breast cancer cells that have p38γ 
knocked down by a small hairpin RNA (shRNA) have a dramatically modified 
cytoskeleton and significantly reduced cell speed compared to scrambled control 
cells (118); however, whether a functional link exists between these two 
observations has yet to be determined, and is the subject of this paper. To 
understand the role played by the p38γ-mediated cytoskeletal modifications, we 
developed a computational study of the mechanics of cell motility and 
locomotion. 
 
Our computational study consists of a numerical, finite element treatment of the 
partial differential equations that govern the mechanics of cell structure and 
motion. Using this approach, we show that p38γ-mediated cytoskeletal changes 
are sufficient to account for the altered motility of cells lacking p38γ. In the course 
of this computational study we have discovered—and subsequently verified 
experimentally—a dynamic leading edge behavior in which motile cells develop 
oscillatory variations in the period and amplitude of actin filament protrusions 
depending upon their specific cytoskeletal architectures. Using input gathered 
from our cell biological experiments into the model, we were then able to derive a 
mechanistic sequence of events leading from p38γ knockdown to the observed 
motility defect. The study presented here (a) shows that p38γ is responsible for 
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driving the mesenchymal-like motility of aggressive breast cancer cells by 
regulating their cytoskeletal architecture, (b) uncovers a novel leading edge 
behavior used by motile cells, and (c) demonstrates the basic mechanical 


























Quick Guide to Equations and Assumptions 
The partial differential equation that governs the quasi-static balance of linear 
momentum of the cell is more amenable to computational solution when it is 
written in weak form. This form is an integral representation that exploits 
integration by parts to allow the use of less-smooth functions for numerical 
approximations: 
Equation 1: Find u such that for all w, 
∫ sw:σ(ε(u)) dV = 0, 
where u is the displacement field vector, w is the weighting function vector, 
and σ(ε(u)) is the stress tensor, here written to emphasize its dependence on 
the displacement field via the strain tensor ε(u). The symbol s denotes the 
symmetric part of the gradient operator. 
Major assumptions: At the typical speeds of cell motility, the effect of inertia is 
negligible, and the ―dynamic‖ balance of linear momentum need not be 
considered. 
Equation 2: The strain tensor is defined as 
ε(u) = su. 
Major assumptions: The infinitesimal strain theory is assumed to hold, 
according to which nonlinear dependence of ε upon u can be neglected. This 
assumption makes for a simpler mathematical formulation and more rapid 
computations. The fully nonlinear theory leads to some quantitative 



























Equation 3: The stress-strain response of the actin fibers and cell membrane 
is governed by the constitutive equation: 
σ = λItr(ε) + 2με, 
where λ and μ are Lamé parameters defined in terms of the more familiar 
Young‘s Modulus E and Poisson ratio ν by 
λ = νE/((1+ν)(1-2ν)) and μ = E/2(1+ ν) 
Major assumptions: The actin fibers and cell membrane are assumed to be 
elastic. This assumption implies that viscous effects associated with the 
kinetics of binding/unbinding of actin monomers with the cytoskeletal fibers 
and with the lipid bilayer will not be accounted for in the stress computations. 
We note, however, that the purpose of the computational model in this work is 
to represent the kinematics of cell motility and locomotion, and not to provide 
a precise computation of the stress. With more appropriate visco-elastic 
models for the actin fibers and cell membrane, the stress computed is more 
physically accurate, but the fundamental conclusions reached on cell motility 
and locomotion do not change. The viscoelastic models also result in a more 
complicated mathematical formulation, and slightly slower computations. 
 
Equation 4: The matrix-vector version of the weak form (Equation 1) is: 
Kd = F 














Table 4.1: Mechanical properties of sub-cellular structures in the computational 
cells. Typical numerical values from Phillips et al(119). 
 
Cell structure Young‘s Modulus, E 
(GPa) 




1.0 0.35 60—110 
Cell 
membrane 
0.00002 0.35 15 
Computational cell type Diameter of enclosing circle (μm) 
Scrambled 46 
Shp38γ 59 
of the mechanical properties, d is the vector of nodal displacements and F is 
the external force vector. The latter includes the effect of displacement 
boundary conditions that model the attachment of the cell to the substrate at 
focal adhesions. 
Major assumptions: Our finite element implementation is based on the plane 
stress model of mechanics as explained in the text under ―The computational 
cell model.‖ Plane stress is an appropriate model for the two-dimensional 
shape adopted by cells on a substrate. 
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Table 4.2: Computational cell dimensions measured on live cells. For the 
scrambled cell, the reported diameter corresponds to the cell shape before it 
stretches, as shown in Figure 4.2C, top row, first panel. 
  
Results 
p38γ knockdown drastically alters actin cytoskeletal architecture 
We previously observed that MDA-MB-231 breast cancer cells with p38γ 
knocked down (―shp38γ cells‖) have strikingly different cell shapes and 
disorganized actin cytoskeletons compared to MDA-MB-231 scrambled control 
cells (―scrambled cells‖) (118). Scrambled cells form long actin stress fibers 
traversing the length of the cell, well-aligned along the long axis. Furthermore, 
these cells develop leading edge filopodia, and the entire cell body is polarized in 
the direction of the stress fibers. In contrast, while shp38γ cells have thick actin 
bundles resembling the stress fibers in the scrambled cells, these fibers are 
primarily confined to the leading edge. The leading edge architecture is 
characterized by the formation of lamellipodia-like structures to which the actin 
bundles lie parallel. The cell shape is strikingly more rounded than the scrambled 
cells. To quantitatively address the cell shape and cytoskeletal differences 
between scrambled and shp38γ cells we measured aspect ratios of the cells, and 




Scrambled cells had aspect ratios (defined as the dimension perpendicular to the 
leading edge divided by the dimension parallel to the leading edge) of ~4, 
whereas the p38γ cells had aspect ratios < 1 (Figure 3.1A from Ref. 4). 
 
The actin stress fibers are well-polarized in scrambled cells and oriented at 3.42º 
± 1.89º (mean ± std. dev.) on either side of the normal to the leading edge 
(Figure 4.1B). This structure is consistent with the scrambled cell 
protrusive/contractile mode of motility (Movie 1). The actin bundles in the shp38γ 
cells, however, have a bimodal orientation distribution at 61.08° ± 3.94º (mean ± 
std. dev.) on either side of the normal to the leading edge, thus differing 
significantly from scrambled cell cytoskeletal architecture (Figure 4.1B).  The 
lamellipodia-like structures associated with these actin bundles are observable 
during shp38γ cell motility (Movie 1), but show little similarity to classic 
lamellipodial cytoskeletal architecture, which normally consists of thin branched 
actin filaments forming a protrusive meshwork (103). 
 
p38γ knockdown also had a profound effect on the modes (qualitative 
appearance) of cell motility and locomotion (Figure 4.2A), and on the speed 
(Figure 4.2B). Scrambled control cells moved in a mesenchymal manner, forming 
long filopodial projections that adhered to the substrate at the cells‘ leading edge.  
The cells then could ―pull‖ themselves forward in alternating cycles of leading 
edge protrusion and trailing edge retraction—the latter presumably being 
facilitated by stress fiber contraction (Figure 4.4A, top, and Movie 1). shp38γ 
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cells, however, appeared to have difficulty polarizing and were unable to form 
long pseudopodia (Figure 4.4B, top, and Movie 1). The cells moved inefficiently, 
using a broad lamellipodia-like structure, with apparent oscillations of the whole 
cell body in the direction parallel to the leading edge, and exhibited failures of 
detachment at the rear of the cell. 
 
Computational modeling reveals that p38γ-induced changes in cytoskeletal 
architecture influence cell motility 
We observed that p38γ knockdown had functional (impaired motility and other 
metastatic properties) and structural (actin cytoskeleton and cell shape) effects 
on MDA-MB-231 cells (118). However, this left open the question of whether the 
change in actin cytoskeletal structure is sufficient to impair motility in the manner 
we observed. Since it remains inaccessible to experiments, this central question 
was addressed by computational modeling.  
 
Our computational models use the finite element method to solve the partial 
differential equations that govern the mechanics of cell motility (see Materials 
and Methods for modeling details). We hypothesized that the strikingly different 
cytoskeletal architecture; i.e., polarized stress fibers in scrambled versus bimodal 
bundles of fibers in shp38γ cells, underlies the observed differences in motility. 
 
To test this hypothesis we first created the computational model of scrambled cell 
motility. Using the typical dimensions of scrambled cells (Table 4.2/Figure 4.1A), 
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their observed cytoskeletal morphology of ±3.42º (Figure 4.1B), and using the 
mechanical properties of actin stress fibers and cell membrane of mammalian 
cells (Table 4.1) we varied the rates of actin filament protrusion and retraction as 
inputs to the model to successfully recreate the observed motility and locomotion 
of live scrambled cells (Figure 4.2C, top panel, and Movie 2). 
 
To determine whether actin cytoskeletal architecture is one of the defining 
features driving motility of the two MDA-MB-231 phenotypes, we next created the 
computational model of shp38γ cells with the cell dimensions reported in Table 
4.2 and Figure 4.1A and cytoskeletal morphology of actin bundles at ±61.08º 
reported in Figure 4.1B. The mechanical properties of the actin fibers and cell 
membrane were the same for shp38γ as for the scrambled cells (Table 4.1). 
Running the computational shp38γ cells exactly as the computational scrambled 
cell was unsuccessful. In particular, allowing the two families of stress fibers at 
±61.08º to extend and retract synchronously (in phase) produced computational 
shp38γ cell motion that was characterized by large leading edge ruffles but none 
of the oscillations in whole cell motion in the parallel direction to the leading edge 
that are evident in Movie 1. Since this computed motility bore little resemblance 
to the live shp38γ cells, we conjectured that the observed shp38γ motion was 
due mainly to the two families of actin bundles at +61.08º and -61.08º alternating 
(out of phase) in their protrusion and retraction. When incorporated, these 
dynamics, even without being precisely timed, produced a disjoint crawling 
motion with oscillations of the cell body in the direction parallel to the leading 
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edge of the computational shp38γ cell. This motility was remarkably similar to our 
live shp38γ cell motility (Figure 4.2C, bottom and Movie 2). These results 
suggested that actin cytoskeletal architecture is important for defining shp38γ cell 
motility, however further experiments were necessary to separate the influence of 
actin fiber orientation from actin protrusion/retraction dynamics.   
 
Live scrambled and shp38γ cells have oscillating leading edge protrusions 
The computational shp38γ cell motility thus revealed the possibility of a novel, 
previously unobserved aspect of cellular dynamics, namely waves of protrusion 
at the leading edge of a migrating cell that alternated between differentially-
oriented families of actin fibers. Oscillations in retraction of the trailing edge of 
keratocytes have been previously observed (120) and regular, periodic changes 
in cell shape are important for productive cell movement (121). To our 
knowledge, however, such behavior has never been observed or characterized in 
the leading edge of motile cells, yet our computational study suggested that it is 
required for the observed shp38γ cell motility. To test this prediction of the model 
we studied in detail the dynamic behavior of the leading edge of scrambled and 
shp38γ cells stably transfected with RFP-actin.  
 
Using time-lapse microscopy and standard imaging edge detection techniques 
(see Materials and Methods), we observed remarkable differences in leading 
edge protrusion between scrambled and shp38γ cells (Figure 4.3A and 4.3C). At 
first observation, scrambled cells appeared to protrude forward in one continuous 
110 
 
motion while shp38γ cells showed evidence of alternating left- and right-of-center 
protrusions corresponding to the two families of actin bundles at ±61.08º (Figs. 
3A and 3B). Upon closer analysis, leading edge protrusion in both cell lines 
actually manifested as alternating between left-of-center and right-of-center 
leading edge regions (Figs. 3B and 3C). (In the case of scrambled cells these 
regions correspond to the stress fibers at ±3.42º). The crucial difference between 
the cell lines was the time period between left and right protrusions; this period 
was much longer (4.83 ± 1.09 minutes) in shp38γ cells than in scrambled cells 
(1.75 ± 0.14 minutes) (Figure 4.3D). This periodicity is evident in the time lapse 
videos as the noticeably disjoint crawling motion of the shp38γ cells, contrasting 
the coordinated protrusion/retraction cycle of the scrambled cells (Movie 1). Also 
note the larger amplitudes of leading edge protrusions in shp38γ than in 
scrambled cells (Figure 4.3C). 
 
These live cell results confirmed the prediction of the computational model. We 
repeated our computational cell motility studies with the mean left/right leading 
edge protrusion amplitudes and time periods of oscillation, and trailing edge 
retraction rates (Figure 4.3E), which we measured via time-lapse microscopy, 
now used as targets to be met by controlling the actin fiber extension/contraction 
rates in the model (see Materials and Methods). Thus incorporating these 
experimentally-observed leading edge dynamics further refined our 
computational models, showed good agreement between the live and 
computational cells, and importantly did not fundamentally alter the response of 
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the refined computational cell models from the initial models in a qualitative 
sense (Figure 4.4A-B; Movie 3). 
 
Cytoskeletal architecture is a determinant factor of p38γ–mediated cell 
motility 
In order to separate the effects of cytoskeletal architecture from the leading and 
trailing edge dynamics, we tried to ―rescue‖ the phenotype of each computational 
cell by applying the protrusion dynamics (Figure 4.3C-D) of one phenotype to the 
other while maintaining their respective cytoskeletal architectures. Significantly, 
applying the scrambled cell leading and trailing edge behavior to the 
computational shp38γ cell did not restore wild type-like motility to the cell (Figure 
4.5A). Correspondingly, the reverse situation—applying the shp38γ cell leading 
and trailing edge behavior to the computational scrambled cell—did not cause it 
to move like the shp38γ cell (Figure 4.5B), indicating that the leading and trailing 
edge dynamics of each cell type are not sufficient to enable their respective 
forms of motility independent of cytoskeletal architecture.  
 
As a final means of separating the effects of cytoskeletal architecture from 
leading and trailing edge dynamics, we repeated our computational study by 
applying a synthesized motion (leading edge protrusion amplitude = 0.67 μm, 
period = 3 min., trailing edge retraction = 0.5 μm/min) to scrambled and shp38γ 
cells (Figure 4.5C-E). All of these parameters are approximately the means of the 
corresponding values for the live scrambled and shp38γ cells (Figure 4.3C-E). 
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The difference in cell speed between these computational scrambled and shp38γ 
cells, when normalized by computational scrambled cell speed, is remarkably 
similar to the difference between the live experiments in scrambled and shp38γ 
cells, after being similarly normalized by live scrambled cell speed (Figure 4.5C). 
The synthesized motility in the computational cells also is similar to actual motility 
of the live cells in a qualitative sense (Figure 4.5D and E), even though the actual 
speeds observed differ from the corresponding live cell speeds due to the 
synthetic nature of the imposed leading and trailing edge dynamics. This final 
study indicates that, when all other parameters remain the same, modifications in 
cytoskeletal architecture alone are sufficient to impair cell motility in the manner 
we observed experimentally: from creating effective locomotion in live scrambled 




Our models are based on the partial differential equations that govern motion of 
cells (and of all physical systems), and on the constitutive equations that specify 
how the forces (stresses) producing motion in cells are related to the details of 
that motion (strain) itself. These equations were posed in a numerical form 
suitable for efficient computation by the finite element method. This method uses 
a tessellation of the geometry of the cell, which is seen in Figure 4.S1. This 




Using the computational cell model in combination with our live cell microscopy 
studies, we showed that p38γ promotes breast cancer cell motility at least in part 
by mediating actin cytoskeletal remodeling, and thereby creating proper stress 
fiber orientation. Using the computational cell models, we first noted that whereas 
the observed whole cell locomotion could be produced by simultaneous action of 
all the observed stress fibers in scrambled cells, the experimentally observed 
ineffective locomotion of shp38γ cells was only possible if the action alternated 
between the two families of actin bundles seen in this cell phenotype. (We note 
that this question would prove difficult to address using cell biological techniques 
alone.)  
 
The resulting mode of motility of the computational shp38γ cell model (Figure 
4.2C and Movie 2) strongly resembled that of the corresponding live cells (Movie 
1), suggesting that this computationally-inspired model of alternating action of the 
actin bundle families is representative of what is occurring in live cells. In live cell 
microscopy, prominent oscillations were observed at the leading edges of both 
cell types (Figure 4.3A), so we focused our analyses on this specific location in 
the cell. The method of normalizing leading edge protrusions explained in 
―Materials and Methods‖ (also Figure 4.3B-D) highlights the differences between 
the chosen regions, here called left- and right-of-center of the leading edge 
prompted by the distinct orientations of actin bundle families in the shp38γ cells 




Leading edge protrusions are caused by actin filament polymerization (122-129). 
This is an inherently stochastic process due to the timing of arriving actin 
monomers, and is controlled also by upstream signaling events. Given this 
stochasticity, our method of normalization (Figure 4.3A-D and caption) is bound 
to yield out-of-phase oscillations of the left- and right-of-center protrusions. It is 
notable, however, that when shp38γ cells are compared with scrambled cells, the 
amplitude of these oscillations is larger by a factor of ~5, and the period by a 
factor of ~3 (with statistical significance), as seen in Figure 4.3C-D. The smaller 
amplitude and period of oscillations in the scrambled cells also serve to validate 
our initial model in which all stress fibers acted simultaneously in the 
computational model of these cells (Figure 4.2C). The association of left- and 
right-of-center leading edge regions with differentially-oriented families of actin 
fibers (Figure 4.1B and 3B)  and the magnification of amplitude and period 
differences, with increased spread in orientation of these families suggests an 
important link between cytoskeletal morphology and actin protrusion dynamics.  
 
While the computational model could be considered already validated by the 
confirmation of its prediction of alternating protrusions in shp38γ cells, we further 
tested it by incorporating the measured dynamics of leading edge protrusion and 
trailing edge retraction from Figure 4.3C-E. In these refined computations, the 
computational scrambled and shp38γ cells demonstrated motility and locomotion 
that were remarkably similar to the corresponding live cells (Figure 4.4A-B, 
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respectively). We consider this to be confirmation of the robustness and accuracy 
of our computational model of cell motility and locomotion. 
 
Further investigation on the interaction of protrusion/retraction dynamics and 
cytoskeletal architecture (Figure 4.5) revealed that the measured leading edge 
dynamics cannot be divorced from the cytoskeletal morphology and cell shape, 
but rather they are interdependent. The leading edge dynamics reported in 
Figure 4.3C and 3D were obtained by averaging the protrusions at 8 points each 
along the left- and right-of-center leading edge regions of the respective cells. 
Since the leading edge shape and dimensions of scrambled and shp38γ cells are 
significantly different (see Figure 4.1A), the dynamics data obtained at points 
along their leading edges cannot be transposed from one cell type to the other in 
a consistent manner. These dynamics therefore seem inseparable from cell 
shape and cytoskeletal morphology. We note that this investigation of 
transposing dynamics with cell shape and cytoskeletal morphology is not 
possible without a computational model such as the one presented here, and is a 
powerful test of robustness of the predictions of the original model. 
 
Our final computational investigation with synthetic motility further strengthens 
the idea that cell shape and cytoskeletal morphology have primacy in effecting 
motility and locomotion: With the same leading/trailing edge dynamics and 
mechanical properties but different cell shapes and cytoskeletal morphologies, 
the ratio of speed of scrambled and shp38γ cells is the same in the 
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computational cell models as in live cells. Since these synthetic dynamics were 
chosen so that the amplitude and period were each the average of the live 
scrambled and shp38γ cells, they did not bias the computational cell models 
toward either the scrambled or shp38γ phenotype. The actual speeds of the 
computational cells with these synthetic data therefore differed from the 
corresponding live cell speeds. 
 
This finding of their inseparability sharpens the question of exactly how the 
leading edge actin dynamics are linked to cell shape and cytoskeletal 
morphology. While this is a subject for future investigation, we do speculate on 
the chain of events: p38γ knockdown  changes in cytoskeletal architecture  
changes in cell shape  compensatory changes in leading edge protrusion 
periodicity  changes in cell motility.  
 
Oscillation of other components of cell motility, such as cell shape (130) and 
trailing edge retraction (120), have already been shown to be essential for 
productive cell motility in Dictyostelium (130) and fish keratocytes (120). We 
expect that further investigation will uncover links between these processes and 
leading edge protrusion oscillations.  
 
As explained in ―Materials and Methods‖, we did not model the details of the 
leading edge actin filament network. Instead, we simplified cell motility into 
leading edge protrusion, adhesion, and trailing edge retraction. A more detailed 
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cytoskeletal model than this would be more faithful to sub-cellular morphology 
and result in some quantitative differences in computed whole cell movement, 
but would not change the fundamental conclusions reached by our computational 
study. By parametrizing the inputs to our computational cell models at just 8 
points along each side (left and right) of the leading edge and 8 points along the 
trailing edge, the computations reproduce the dominant features of whole cell 
movement in quantitative and qualitative terms (Figure 4.4A and 4B). As argued 
above, this demonstrates the determining role played by cytoskeletal architecture 
in cell motility and whole cell locomotion. 
 
The acquisition of motility properties by normally stationary epithelial cells is a 
defining characteristic of breast cancer metastatic progression (86). Motility itself 
is a product of an array of factors: intra-, inter-, and extracellular. Physical models 
integrate these diverse influences governing cell behavior by focusing on 
behavioral outputs (actin protrusion/retraction, whole cell movement, and the 
like), without necessarily concerning the specific genetic pathways dictating this 
behavior. This approach allows mechanistic interrogation of cell behavior or, as 
in the work presented here, mechanistic physical investigation of a specific 
genetic alteration; investigation that bridges the gap between signaling 
modifications (typically the subject of genetic and molecular biology studies) and 
cell behaviors (the focus of cell biology approaches). The fact that this broad 
incorporation of events yielded the discovery of a specific cellular behavior in our 
study reflects the utility of physical modeling in answering, and even creating, 
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specific mechanistic biological questions. Work such as this speaks to the power 
of physical cancer models to supplement, and even fuel, traditional genetic and 
molecular studies. 
 
Materials and Methods 
Reagents 
shRNA was purchased from Open Biosystems through the University of Michigan 
Life Science Institute High Throughput Screening Core. 
 
Cell Lines 
Untransfected MDA-MB-231 were cultured in RPMI 1640 supplemented with 
10% fetal bovine serum. Selection media for shRNA-transfected cells consisted 
of standard cell line media containing 1μg/ml puromycin. MDA-MB-231 stably 
transfected with both shRNA and RFP-actin were cultured in standard cell line 
media containing 1μg/ml puromycin and 350μg/ml G418. All cell lines were 
grown at 37°C in a humidified 5% CO2 incubator. 
 
Transfections 
Two μg of pGIPZ plasmid containing either scrambled or p38γ-specific shRNA 
were nucleofected into 50-70% confluent MDA-MB-231 cells according to the 
manufacturer‘s protocol (Lonza). Nucleofected cells were selected in puromycin 
and further isolated by FACS sorting for GFP. RFP-actin was inserted into these 
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cells using the same technique, using G418 for selection followed by FACS 
sorting for RFP. 
 
Time-Lapse Microscopy 
DIC and RFP time-lapse videos were captured at 37°C using a Deltavision RT 
Live Cell Imaging System equipped with UPlanApo 20x/0.7 NA and 40x/1.2 NA 
lenses at the University of Michigan Microscopy and Image Analysis Lab. Images 
were acquired using SoftWoRx 3.5.1 software. For cell motility analysis images 
were captured every 10 minutes, and for leading edge protrusion analysis 
images were taken every 1 minute. Cell motility videos were enhanced and 
analyzed using Imaris (Bitplane Scientific Software), from which the average 
speed of each cell line was calculated in μm/hour, while leading edge protrusion 
videos were analyzed using ImageJ and Matlab (www.matlab.com). 
 
Actin Immunocytochemistry 
Fifty-70% confluent cells were fixed with 4% paraformaldehyde. Cells were then 
incubated in 1:50 AF568-phalloidin in PBS (Invitrogen) for 10 minutes, rinsed 
once in PBS for 5 minutes, and mounted with Prolong Gold anti-fade with DAPI. 
Images were acquired at room temperature using a Zeiss LSM 510 Meta laser-
scanning microscope equipped with a C-Apochr 40x/1.2 NA and LSM 510 
software. Each channel was imaged sequentially using multitrack recording 




Actin Angle Analysis 
The average stress fiber angles relative to the leading edge were measured 
using ImageJ. See Figure 4.1B. 
 
Leading Edge Protrusion Analysis 
Time-lapse videos of MDA-MB-231 scrambled and shp38γ cells expressing RFP-
actin were generated for cell membrane protrusion analysis. Matlab‘s Image 
Processing tool box was used to convert the RGB images captured by the 
microscope to grayscale images of the same size (using the function rgb2gray). 
Each grayscale image was then converted into binary black/white images based 
on the threshold pixel intensity, which was determined using the image histogram 
(function imhist).  After thresholding the intensity varied from 1 (white) for the cell 
to 0 (black) for the background. Comparison of the black and white images with 
the original RGB images showed no significant loss of accuracy in cell pixel area 
(imtool, pixel region comparison tool). The edge detection algorithm (edge) was 
applied to each binary image in order to create a one pixel-wide cell edge. We 
then created a new sequence of images, each containing the cell edges from two 
successive time points. These cell edge data were also used to compute cell 
centroids at each time instant. 
 
The edge-detected images were next used to compute the distance between 
sections of the leading and trailing edge: A unit vector indicating the direction of 
cell motion was obtained by connecting the cell‘s centroids at two successive 
time instants. A number of pixels were selected on each section of the leading 
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and trailing edge and connected with the corresponding pixels on the edge at the 
next time instant using the unit vector for cell motion between these time instants. 
These pixel-to-pixel distances were tabulated, averaged and then converted to 
physical length units (microns), using the pixel:length ratio given for the 
microscope image. For microscope images with poor contrast, we used ImageJ 
software to manually choose pixels on the cell edge at each time instant. The 
subsequent steps remained the same. 
 
Finally, we defined left- and right-of-center regions of the cell leading edge as 
demonstrated in Figure 4.3B. The motion of selected points on the left- or right-
of-center regions was averaged over each time interval and subtracted from the 
motion of the center. These relative protrusions are shown in Figure 4.3C and the 
half-period of the resulting oscillations are plotted in Figure 4.3D. 
 
The Computational Cell Model 
A cell‘s motility is determined by its deformation in response to internal forces 
generated by actomyosin contractility. These phenomena are governed by the 
quasi-static balance of linear momentum, also referred to as the mechanical 
stress equilibrium equation. Our treatment of this partial differential equation is 
based on Equation 1 (see Quick Guide to Equations and Assumptions for all 
equations). The mechanical response of the cell and its sub-structures is 
described mathematically by the strain (Equation 2) in response to the 




We have used two-dimensional models that represent the cells as seen on a 
planar substrate—the so-called plane stress approximation in continuum 
mechanics.(131) These models treat the cells as mechanical structures, with 
actin stress fibers having the mechanical behavior of thin beams, focal adhesions 
as fixed supports but allowed to change in time, and the cell wall as a thin 
membrane. Equations 1—3 are combined, and written in numerical form 
(Equation 4) suitable for computational solution by the finite element method 
(132).This is a mathematical technique for numerical solution of partial differential 
equations written in weak form, such as Equation 1. In the finite element method, 
Equation 1 is first approximated in a mathematically rigorous manner in terms of 
matrices and vectors (Equation 4) before solving it by using numerical techniques 
from linear algebra. The matrix-vector approximation is obtained by 
approximating the spatial domain of interest (in this case, the cell) as a mesh 
consisting of nodes and elements. The nodes are points on the cell and the 
elements are patches over which the mechanical response is averaged in a 
mathematically-rigorous manner. Using the commercial finite element package 
ABAQUS v6.8, we developed meshes for the scrambled and shp38γ cells. We 
use 3-noded continuum plane stress finite elements. The mesh of the scrambled 
cell used 1278 elements and that for the shp38γ cell used 2671 elements, 
respectively. See Figure 4.S1 for a detail of a typical finite element mesh. See 
Table 4.1 for thicknesses of actin fibers and cell membrane in the computational 




The mechanics of motility and locomotion were recapitulated as follows: The 
sequence of actin polymerization, focal adhesion formation, and stress fiber 
retraction was imposed by prescribing the rates of extension/contraction of the 
mesh regions representing actin fibers by specifying the inelastic strains of these 
regions, and anchoring of the boundary points that represent stable focal 
adhesions.  
 
In these exploratory computations we did not model the structural details of 
leading edge lamellipodial/filopodial protrusion due to polymerization of the 
leading edge actin filament network. Instead, leading edge protrusion as well as 
trailing edge retraction due to actomyosin stress fiber contractility were modeled 
as follows to recapitulate their roles in cell locomotion. The actin cytoskeleton 
was represented by generic fibers (Figure 4.2C, 4.4A, 4.4B, 4.5A, 4.5B, 4.5D, 
4.5E). Each actin fiber was constrained to remain stationary at a chosen point 
along its length, which models a focal adhesion. The filament was thus divided 
into leading and trailing parts. The leading part could only extend, thus modeling 
cell leading edge lamellipodial/filopodial protrusion due to actin filament 
polymerization. The trailing part could only contract, thus modeling cell trailing 
edge retraction due to actomyosin contractility. Each such fiber was allowed to 
either extend while its trailing end was held stationary to model protrusion, or to 
contract while its leading end was held stationary to model retraction. We note 
that this combination of mechanisms has been proposed previously by Svitkina 
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et al. (133). Also see Ridley et al. (37) and Pollard et al. (134).  In this work, we 
have proven that this mechanism leads to locomotion, if the laws of mechanics 





Figure 4.1 - p38γ knockdown alters cell shape and cytoskeletal 
architecture. (A) Cell shape difference by aspect ratio (L/W) (*p<0.05, n = 35 for 
scrambled and shp38γ, scale bar = 25 μm ). Data are represented as ± SEM. 
This figure is from Ref. 4 (B) Scrambled cells have well-defined stress fibers and 
leading edge filopodia (top right corner of corresponding image). shp38γ cells 
have bimodally-oriented actin fibers that are parallel to leading edge lamellipodia 
(upper edge of corresponding image). Stress fiber angles are measured as 






Figure 4.2 – Computational mathematical modeling nominates cytoskeletal 
architecture as the force driving p38γ-mediated cell motility. (A) p38γ 
knockdown impairs locomotion of MDA-MB-231 cells: Panels show the longer 
tracks made by scrambled control cells versus the shp38γ cells. (B) This is 
further supported by bar graphs on the right showing cell speeds in μm.hr-1. The 
average speed of scrambled cells is twice that of shp38γ cells (*p<0.01, n = 19 
cells for scrambled, n = 24 cells for shp38γ, data are ±SEM). Both (a) and (b) are 
from Ref. 4. (C) Preliminary computational models of scrambled and shp38γ cells 
using the observed cell-scale dynamics of leading or trailing edge protrusion or 
retraction, respectively. Note the development of a filopodium at the leading edge 
of the scrambled cell. Arrows point to out of phase lamellipodial oscillations 
arising from the two distributions of actin fibers in shp38γ cells. The actin fibers 
are in red and the nucleus is blue. The models successfully represent the 
coordinated locomotion of scrambled cells, and the oscillatory motility but 





Figure 4.3 – The leading edge protrusion dynamics predicted by the in 
silico shp38γ model occur in live cells, and these behaviors differ between  
scrambled and shp38γ cells. (A) Kymographs of leading edge protrusion in 
scrambled and shp38γ cells. (B) Detail showing the ―left-― and ―right‖ sides of the 
leading edges of scrambled and shp38γ cells. (C-D)  Dynamics of left and right 
sides of cell leading edges. Leading edge velocities from the highlighted regions 
in (B) are represented graphically (C). The reference velocity is set such that 
total forward displacement equals zero; thus, forward movement greater than the 
average of left and right appears positive, and forward movement less than the 
total average appears negative. (D) The half-period in (C) (average time between 
left-right intersections) is significantly longer for shp38γ cells than scrambled cells  
(*p<0.0072, n = 3 for each cell line). Data are representative of three 
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independent experiments and are represented as ± s.e.m. (E) Trailing edge 
motion of scrambled and shp38γ cells plotted as the incremental displacement 
between successive time instants. For scrambled cells the most rearward point 
was chosen. For shp38γ cells the positions were averaged over 8 points evenly 






Figure 4.4 - Incorporating experimentally-derived leading edge protrusion 
dynamics into in silico scrambled and shp38γ cells more accurately 
represents, but does not change the fundamental behavior of, cell motility 
in the models. Time lapse images of RFP-actin-transfected scrambled (A) and 
shp38γ (B) cells (scale bar = 20 μm). Note the successful trailing edge retraction 
in scrambled, but not in shp38γ cells. Finite element computations for each cell 
type computational, shown below the corresponding live cell images, accurately 
model cell locomotion using only the morphology of the actin fibers (red) from 
Figure 4.3 to actuate the dynamics of actin filament protrusion at the cell leading 
edge (see Figure 4.5 for control experiments), and trailing edge retraction by 
actomyosin contractility. Together with the results of Figure 4.5, this validates the 
accuracy of our computational mechanical model in resolving whole cell 





Figure 4.5 – Cytoskeletal architecture, not leading edge protrusion 
dynamics, defines cellular motility. (A) Motility of computational shp38γ cells 
obtained by transposing leading/trailing edge actin dynamics from scrambled 
cells does not rescue the ineffective locomotion of shp38γ cells. (B) Transposing 
leading/trailing edge dynamics of shp38γ cells on computational scrambled cells 
results in motility and locomotion that is unphysical. (C) Ratio of computational 
cell speeds from synthetic motion (see text for details) is the same as ratio of live 
cells. (D-E) Synthetic motility of computational shp38γ and scrambled cells is 




Movie 1: The motility and locomotion of scrambled (left) and shp38γ (right) live 
cells. 
 
Movie 2: The motility and locomotion of preliminary models of scrambled (left) 
and shp38γ (right) in silico cells. 
 
Movie 3: The motility and locomotion of enhanced models of scrambled (left) and 
shp38γ (right) in silico cells, incorporating the leading edge protrusion and trailing 








 Figure 4.S1. Detail showing the finite element mesh with elements (triangles). 























This chapter represents a ―manuscript in submission‖ currently in review at 
Cancer Research under the title ―Computational mechanical modeling reveals 
the role of p38γ in shaping the cytoskeleton and controlling locomotion of 
aggressive breast cancer cells‖ by Devin T. Rosenthal, Harish Iyer, Silvia 
Escudero, Zhifen Wu, Liwei Bao, Hector Garcia, Alejandra C. Ventura, Ellen M. 
Arruda, Krishna Garikipati, and Sofia D. Merajver. 
Figure 4.S2. Synthetic leading edge protrusion/retraction dynamics used to 
separate the effect of actin dynamics from cell shape and cytoskeletal 
morphology. The definition of left- and right-of-center regions and their 
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Conclusions and Future Directions 
 
Conclusions 
Cancer metastasis is a complex, multi-faceted process, and has accordingly 
been a tremendous obstacle for researchers and clinicians to fully understand 
and overcome. Despite its complexity, metastasis can be broken down into 
simple, overarching questions that address metastatic behavior. Here we 
interrogated the following two questions in an attempt to unravel metastatic 
complexity: What causes a cancer cell to become metastatic, and what then 
enables the metastatic behaviors of an already-metastasizing cancer cell?  
 
Through our investigations we discovered that RhoC is an essential switch for 
determining whether or not a cancer cell is metastatic—even within the already 
aggressive cancer stem cell population. Once a breast cancer cell is metastatic, 
we found that p38γ mediates many of the mesenchymal-like metastatic 
properties of the metastasizing cell. Using a novel fusion of computational 
modeling and cell biology we dissected a physical mechanism by which p38γ 
regulates breast cancer cell motility, and in doing so discovered a new physical 




This work directly addresses the aforementioned questions and provides some 
answers; however, as with most scientific endeavors, the results yield more new 
research avenues and questions than they do concrete conclusions. Here we 
elaborate on the conclusions from this body of work and offer several 
perspectives on future research aimed at more deeply interrogating the questions 
raised by our current findings. 
 
RhoC and breast cancer stem cells 
We discovered that RhoC is both necessary and sufficient for breast cancer stem 
cell (BCSC) metastasis (Chapter 2). That RhoC contributes to breast cancer 
metastasis in general is neither surprising nor unprecedented—RhoC has 
previously been shown be necessary for breast cancer metastasis (55) and to 
induce metastatic properties in vitro in otherwise benign mammary epithelial cells 
(51, 95). The novelty of the current findings lies in the sufficiency for RhoC 
overexpression alone to induce metastasis, and the ability of RhoC to dictate 
metastasis of the BCSC population. 
 
Until recently, the implicit assumption within the CSC field was that CSCs were a 
homogenous minority within an otherwise heterogeneous tumor. Though never 
directly stated as such, the majority of experiments focused on the CSC 
population as a whole—are CSCs tumorigenic, can CSCs be serially passaged, 
does the abundance of CSCs confer a worse prognosis—in effect neglecting any 




Recent studies identified subpopulations within the bulk CSC population that are 
required for metastasis (25, 26), suggesting that functional heterogeneity may 
exist within the CSC population. However, these studies identified 
subpopulations based on molecular markers and their necessity for metastasis, 
not molecular promoters that are sufficient for metastasis; therefore, the 
metastatic catalyst(s) remained undetermined. Although many genes are 
necessary for metastasis, few are sufficient, and likely even fewer are sufficient 
to alter the metastatic potential of a stringently selected population of cells such 
as CSCs. Here we identify RhoC as one such gene—to our knowledge the first 
identified molecular promoter of BCSC metastasis.  
 
The work of Hakem et al. has been the defining in vivo work on RhoC in breast 
cancer metastasis for half a decade (55). Hakem and colleagues elegantly 
demonstrated that RhoC is dispensable for tumorigenesis but necessary for 
metastasis. The reciprocal experiment, however—determining RhoC sufficiency 
to induce breast cancer metastasis—has never been performed. Determining 
sufficiency separate from necessity is essential for understanding the switch to 
metastasis; a transition most clearly demonstrated by aggressive breast cancer 





Using IBC as a paradigm for metastatic progression, one can begin to grasp the 
importance of delineating sufficiency from necessity. IBC rarely presents with a 
cohesive primary tumor and therefore, as mentioned, is metastatic from its 
earliest stage. By defying the normal progression of epithelial cellprimary 
tumormetastasis and instead sublimating from normal to metastatic, one would 
expect that the genes driving IBC are therefore sufficient to induce metastasis, 
irrespective of their tumorigenic potential. 
 
As previously described (see Chapter 2), RhoC is necessary for breast cancer 
metastasis (52, 55), RhoC is overexpressed in IBC (85, 135), IBC has a high 
prevalence of BCSCs in lymphovascular emboli (136), and BCSCs mediate IBC 
metastasis (24). In light of these correlative connections, we hypothesized that 
RhoC may be sufficient to promote metastasis, and may function within the 
BCSC population.  
 
Our experiments confirmed the previous findings that RhoC is necessary for 
breast cancer metastasis, as metastasis of IBC-derived SUM149 cells was 
significantly impaired following RhoC inhibition. RhoC sufficiency to promote 
metastasis was shown most clearly through ectopic overexpression in the non-
tumorigenic, non-metastatic MCF-10A cell line. Ectopic RhoC overexpression 
was sufficient to promote MCF-10A metastasis independent from primary tumor 
formation, even within the ALDH (-) population. Taken together, these results 
strongly implicate RhoC as a metastatic oncogene; a gene that, when aberrantly 
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expressed, is capable of specifically inducing metastasis independent of primary 
tumor formation. We do not presume to support or challenge the central tenants 
of the CSC hypothesis here, but rather provide evidence suggesting that, while 
the metastatic potential of cancer cells may be enhanced by CSC identity, it is 
ultimately determined by expression of metastatic oncogenes, such as RhoC. 
 
Interestingly, the relative abundance of BCSCs within both cell lines fluctuated 
according to RhoC expression. Links between RhoC and stem cell maintenance 
are limited and correlative at best—RhoC expression has been linked to glial 
progenitor cell populations (137) and RhoC is a downstream effector of Notch in 
cervical carcinoma cells (138)—therefore the connection between RhoC 
expression and BCSC population size must be further evaluated. One can 
speculate, though, that perhaps a certain percent of BCSCs within a tumor are 
inherently primed for metastasis. If these cells are metastatic BCSCs from 
inception, inhibiting RhoC as performed here may in effect eliminate that portion 
of the BCSC population and prevent early cancer cell dissemination. Such a 
concept is enticing, however much more research must be conducted to begin to 
test this hypothesis.  
 
p38γ in breast cancer metastasis 
In chapter 3 we investigated the role of p38γ in breast cancer metastasis. We 
discovered that p38γ is necessary for breast cancer metastasis, and is 
specifically involved in mediating mesenchymal-like behaviors such as motility 
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and invasion. This link between p38γ and mesenchymal-like behaviors was not 
entirely unexpected, as we originally hypothesized that p38γ may function in 
basal-like breast cancers based on its known role in muscle development (69, 
71, 72, 74).  
 
All cells within the body are united by a common set of genes. The differences 
between cell types thus lie not in their genomic blueprint, but in the utilization of 
their genetic material. For this reason one should not be surprised to find that, in 
order to behave like a muscle cell, a metastatic breast cancer cell usurps muscle-
specific genes. As Gertrude Stein put it, ―a rose is a rose is a rose‖; in this case a 
non-muscle cell with the underlying genetic potential to behave like a muscle cell 
must utilize the genes used by muscle cells to behave like a muscle cell (―a 
muscle is a muscle is a muscle‖). Data such as that presented here thus strongly 
supports the use of basic developmental research to inform and fuel translational 
cancer research. 
 
p38 MAPK research has long been confounded by apparently conflicting 
results—is p38 pro-apoptotic, anti-apoptotic, pro-motility, or pro-differentiation 
(79)? Here we add to these discrepancies by demonstrating that p38γ 
overexpression and overactivation is an integral component of the basal-like 
breast cancer subtype. Interestingly, inhibiting either p38α or p38β individually 
had no effect on MDA-MB-231 cell behavior, whereas inhibiting either p38γ or 
p38δ had profound impacts (data not shown), indicating that the non-canonical 
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p38 isoforms may function independently in some cancer subtypes. This is 
especially relevant given that the vast majority of p38 research has focused on 
either the α or β isoforms, often without discriminating between the two. The data 
we present here strongly supports further research into the specific contributions 
of each p38 isoform—particularly the non-canonical γ and δ isoforms. 
 
Interestingly, p38γ and RhoC expression are related, as changes in p38γ 
expression affect RhoC protein levels. This regulation is specifically due to 
changes in RhoC ubiquitination—a mechanism of regulation never before seen 
for RhoC. Although RhoC is overexpressed in many types of cancer (51-54), to 
date there is no identified mechanism for this upregulation. Preventing RhoC 
ubiquitination could serve as one such mechanism, and it also provides a 
mechanism for regulating RhoC expression on a short time scale compatible with 
the rapid turnover needed to regulate normal cell motility. Additional research into 
the proteins that regulate RhoC ubiquitination, as well as the biochemical details 
of RhoC ubiquitination, is therefore urgently needed. 
 
 
p38γ and the cytoskeleton 
Using a combination of cell biology and computational mechanical modeling we 
were able to determine a likely mechanistic link between the p38γ–mediated 
effects on cytoskeletal architecture and cell motility. By using computational 
modeling we also discovered, and subsequently experimentally verified, a novel 




The computational models revealed that p38γ-mediated changes in cytoskeletal 
architecture were sufficient to alter MDA-MB-231 cell motility in both the 
qualitative and quantitative manners observed in live cells. Interestingly, this link 
was established in the absence of any genetics (other than p38γ knockdown), 
and was instead simply based on the physical properties of the motile cell—
membrane and actin cytoskeleton rigidity, rates of protrusion and retraction, and 
the like. This work thus represents an alternative paradigm to the traditional 
―mechanistic‖ study. Rather than focusing on cellular signaling mechanisms—
many of which can be compensated for by alternate signaling pathways—we 
focused on the physical, behavioral endpoint of these signaling networks; in 
essence accounting for all possible signaling inputs.  
 
Although such a study does not immediately reveal specific, druggable targets, it 
does provide a systems-wide perspective on aberrant cell behavior (in this 
example, altered cell motility as a consequence of genetic manipulation) that can 
ultimately be used to identify new drug targets. Instead of trying to elucidate the 
individual signaling molecules that enable a phenotypic change, using 
computational mechanical modeling permits one to take a top-down approach. 
By understanding the basic physical properties that contribute to a given cellular 
behavior (here cytoskeletal architecture contributing to mesenchymal-like cell 
motility) one can work backwards; first identifying broad signaling networks that 
contribute to the physical behavior (i.e. cytoskeletal remodelers), narrowing that 
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down to protein families that govern the detailed physical properties underlying 
the cellular phenotype (i.e. Rho GTPases and stress fiber formation), and finally 
delineating the specific signaling molecules driving the observed phenotype (i.e. 
RhoC). Such an approach addresses issues such as crosstalk and compensation 
early on by implicitly incorporating them into the original mechanical model. 
Using signaling-based mathematical modeling and systems biology one could 
also aim to predict potential sources of compensation when therapeutically 
targeting the identified molecular driver (i.e. other Rho GTPases compensating 
for RhoC knockdown), and eventually determine optimal multi-target therapies 
aimed at disrupting a behavior, rather than a specific protein. 
 
Future Directions 
RhoC influence on BCSC population size 
In the course of our analysis of RhoC influence on BCSCs we discovered that the 
abundance of BCSCs within a cell line changes concordant with RhoC 
expression (Chapter 2). These initial observations were made by using flow 
cytometry to compare the percent of ALDH (+) cells between our genetically-
modified cell lines. This exciting and important initial result opens the door to 
more detailed studies investigating the RhoC-BCSC population size connection. 
 
Although our initial flow results were intriguing, further studies need to be 
performed to accurately define the relationship between RhoC and BCSC 
population size. At present we have correlative evidence linking RhoC and BCSC 
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abundance; we now need to functionally evaluate this relationship. One standard 
functional measure of BCSC abundance is the mammosphere assay (139). In 
this assay, breast cancer cells are grown in a specialized suspension culture that 
selects for BCSC growth. Using this assay, we can evaluate whether the percent 
of cells capable of forming mammospheres differs between our RhoC-modified 
cell lines, thereby addressing the question ―does modulating RhoC expression 
affect the abundance of functional BCSCs?‖ 
 
If RhoC does affect BCSC population size, as preliminary data indicates is the 
case, the next logical question is ―does RhoC affect BCSC self-renewal?‖ To 
address this question, mammospheres from the aforementioned experiment can 
be serially passaged. If BCSCs retain their self-renewal abilities regardless of 
RhoC expression, we would expect that the same percent of dissociated cells 
from primary mammospheres generated by each cell line will be able to form new 
mammospheres. 
 
RhoC regulation of p38γ  
We have shown that there is a strong, persistent relationship between p38γ and 
RhoC, and that p38γ can regulate RhoC expression by affecting RhoC 
ubiquitination (Chapter 3). Surprisingly, we have also observed that the reverse 




We assayed p38γ mRNA levels in MCF-10A cells that overexpress constitutively 
active RhoC (10A G14V) compared to vector control MCF-10A (10A vec) and 
were surprised to find that p38γ expression was increased approximately two-
fold in the 10A G14V cells—to nearly identical levels as MDA-MB-231 cells 
(Figure 5.1A).  
 
The strongest evidence to date for RhoC regulating p38γ expression comes from 
a mammary-specific transgenic RhoC overexpression mouse model generated 
by our lab. This model uses the mouse mammary tumor virus (MMTV) promoter 
to drive constitutive mammary-specific overexpression of RhoC. We have also 
crossed this mouse with the tumorigenic and metastatic MMTV-driven Polyoma 
Middle-T (PyMt) mouse to create the PyMt-RhoC double transgenic.  
 
When we assayed p38γ expression in mammary glands from the transgenic 
mouse strains (RhoC, PyMt, and PyMt-RhoC) compared to a control mouse 
(C57BL/6), we found that p38γ protein levels were elevated in all of the 
transgenic strains (Figure 5.1B). Interestingly though, p38γ levels were highest in 
the RhoC-overexpressing mice (RhoC and PyMt-RhoC), suggesting that RhoC 
overexpression is independently capable of increasing p38γ expression. Taken 
together with the cell line data, these findings strongly suggest that RhoC 




To stringently test the hypothesis that RhoC regulates p38γ it is crucial to 
determine p38γ transcriptional, translational, and post-translational expression in 
each of the aforementioned systems (in vitro RhoC overexpression and 
transgenic mouse models). These experiments will allow us to deduce at which 
level of expression RhoC affects p38γ. From these data additional hypotheses 
regarding the RhoC mechanism of action for regulating p38γ can be generated.  
 
If RhoC and p38γ do in fact regulate one another, two questions emerge: 1) do 
these two genes constantly regulate one another, or 2) does one initially activate 
the other (similar to the ―Vogelgram‖ model of cancer progression (140)), which 
in turn maintains expression of the first? It is possible, for example, that during 
breast cancer progression RhoC is first overexpressed. RhoC overexpression 
may then increase p38γ expression, which in turn helps stabilize RhoC protein by 
preventing RhoC ubiquitination, thus maintaining a synergistic activation loop. 
Such a scenario fits with the previously described concept of RhoC as an initiator 
and p38γ as a maintainer of metastasis. 
 
To begin to dissect this complex relationship we must first knock down RhoC in a 
RhoC- and p38γ-overexpressing breast cancer cell line, such as MDA-MB-231, 
and determine the effect on p38γ expression. If p38γ expression decreases in 
this cell line then the two are likely acting in synergy, which fits with example 1 
from the previous paragraph. If p38γ expression is unaffected it is likely that 
RhoC no longer influences p38γ expression, as described in example 2. To 
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further examine the interrelationship between p38γ and RhoC, we will analyze 
expression of each protein in clinical breast cancer samples that span the stages 
of cancer progression—from normal breast to metastatic disease—and 
determine 1) expression of which, if either, protein increases first during breast 
cancer progression and 2) at which point(s) during breast cancer progression 
expression of the two proteins are highly correlated. 
 
Regulation of p38γ activation 
Phosphorylation is the standard mechanism for p38γ activation, and we 
demonstrated that p38γ phosphorylation is higher in breast cancer cells than 
non-tumorigenic mammary epithelial cells (Chapter 3). It is therefore pertinent to 
determine the upstream signaling events contributing to p38γ activation in breast 
cancer. 
 
To address this question we analyzed mRNA levels of several p38 activators in 
MCF-10A vec, MCF-10A G14V, and MDA-MB-231 cells. We found that mRNA 
levels of the two major p38 activators, MKK3 and MKK6, are elevated in MDA-
MB-231 cells compared to non-tumorigenic 10A vec cells (Figure 5.1C). When 
we assayed protein levels of these kinases in the transgenic RhoC models we 
observed that MKK6 expression varied concurrent with RhoC expression, while 
MKK3 expression was unaffected (Figure 5.1D). Interestingly, MKK3 and MKK6 
mRNA levels were not increased in 10A G14V cells (Figure 5.1C), suggesting 
that RhoC may influence expression of MKK6 at the translational or post-
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translational level. This may be mediated in part by affecting MKK3/6 
phosphorylation, as phosphorylation of these two proteins is concomitantly 
increased with elevated RhoC expression (Figure 5.1D). Taken together, these 
data suggest that RhoC is influential on p38 signaling as a whole, and may 
specifically target the p38γ isoform. 
 
Future experiments will assay the phosphorylation levels of MKK3 and MKK6 
separately, as each isoform has been shown to have distinct effects on p38γ 
activation (141). Our experiments thus far suggest that p38γ activation in breast 
cancer cells is constitutive and occurs independent of external factors, which is 
consistent with cancer cells developing independence from extracellular signals 
(86). It is therefore imperative to determine where the upstream activation signals 
leading to constitutive p38γ activation in breast cancer come from, since p38γ 
activation likely stems from an intracellular source (rather than environmental 
stimuli, as is typically the case for p38 in non-tumorigenic cells). The source of 
p38γ activation should be a significant therapeutic target, as it is likely the driving 
force behind a broad array of aberrantly activated signaling pathways. 
 
p38γ influence on focal adhesions and traction forces of migrating cells 
In chapter 4 we analyzed in detail the aberrant motility of shp38γ cells and 
deduced the role of actin cytoskeletal architecture in p38γ-mediated cell motility, 
focusing specifically on stress fiber orientation. Although this study revealed an 
important role for the cytoskeleton in p38γ-mediated mesenchymal-like cell 
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motility, as discussed in Chapter 1, there are many other cellular components 
that contribute to mesenchymal-like cell motility.  
 
Focal adhesions play an essential role in regulating actin stress fiber orientation, 
protrusion, retraction, and localization (31). Therefore, if cytoskeletal architecture 
and protrusion dynamics are affected by a genetic modification—as was shown 
to be the case following p38γ knockdown in chapter 4—focal adhesion 
distribution or dynamics are likely altered. 
 
To investigate the role of focal adhesions in p38γ-mediated cell motility, we 
assayed focal adhesion protein expression levels and localization. Although 
overall levels of vinculin (a focal adhesion component) do not change between 
231 scrambled and shp38γ cells (Figure 5.2A), focal adhesion distribution is 
dramatically altered (Figure 5.2B). In scrambled cells, focal adhesions are tightly 
clustered to the leading and trailing edges of the cell (Figure 5.2B, left), as is 
expected for mesenchymal-like cells (31, 142). By contrast, focal adhesions in 
shp38γ cells are indiscriminately dispersed around the cell periphery (Figure 
5.2B, right), suggesting that shp38γ cells do not completely polarize to designate 
a leading and trailing edge. 
 
Focal adhesions are the physical connections between a cell and its substrate, 
and accordingly are the sites of traction force during cell motility (31, 142); 
therefore, focal adhesions and traction force distribution are intimately intertwined 
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(142). While much research has centered on the genetic and molecular 
determinants of cancer cell motility, relatively little research has focused on the 
physical behaviors of moving cancer cell—specifically which forces characterize 
motile cells, and are consequently required for productive cell motility. 
 
In collaboration with Dr. Jianping Fu we are employing a novel system for 
analyzing traction forces in scrambled and shp38γ cells, termed the micropost 
array device (mPAD) (143). Briefly, the mPAD is a dense array of 
polydimethylsiloxane (PDMS) pillars which cells are cultured on top of. By 
measuring post bending generated by cell-post interactions, the magnitude, 
distribution, and directionality of traction forces exerted by a cell can be 
calculated by a customized MATLAB program (143).  
 
After optimizing the mPAD system for our scrambled and shp38γ cells, we were 
able to measure the traction forces exerted by both cell types. Though 
preliminary, our current data show that, as expected, distribution of traction 
forces in each cell type is roughly the same as focal adhesion distribution (Figure 
5.2C – compare to Figure 5.2B). Interestingly, the overall force exerted by each 
cell type is not significantly different, nor is the vector sum force (Figure 5.2D). 
The differences in force instead lie with both the directionality of cell force, as 
well as the maximum force. The scrambled cell reaches peaks in both total force 
(143 nN) and vector sum force (35 nN) during contraction (Figure 5.2D). By 
contrast, the shp38γ cell total force peaks at 133 nN and the vector sum force 
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oscillates over time and only reaches a maximum of 23 nN, and the cell never 
undergoes rapid, contractile movement (Figure 5.2D). Taken together, these data 
suggest that directional, contractile cell motility requires polarized traction forces, 
and that these forces must be able to reach a certain force maximum. 
 
To further probe this hypothesis, we will analyze additional cells during all phases 
of cell motility (protrusion, elongation, and contraction) to see if a force threshold 
value emerges. In addition, we will divide the forces in these cells into leading 
edge and trailing edge components and observe the specific forces required at 
each end of the cell for efficient cell elongation and contraction. To explore the 
genetic requirements for the observed traction forces and focal adhesion 
distribution, we will perform the same experiments using shp38γ cells that are 
forced to re-express RhoC (see Chapter 3). Since RhoC has been shown to be 
involved in stress fiber formation, contraction, and focal adhesion turnover (40, 
47, 48), we expect that rescuing RhoC expression will redistribute focal 
adhesions in shp38γ cells to more closely resemble scrambled cells, potentially 
allowing shp38γ cells to generate sufficient polarized traction force to produce 
contractile movement. Lastly, these experiments will be extended to additional 
breast cancer cell lines that rely on p38γ for their motility (i.e. BT549 and Hs578t) 
to determine whether our results are broadly applicable. 
 
Once detailed traction force data has been generated and analyzed, we can 
expand our studies into real-time, dynamic analysis of other motility related 
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processes—namely focal adhesion dynamics and cytoskeletal remodeling. By 
transfecting fluorescently-tagged actin and focal adhesion marker (such as 
vinculin or paxillin) expression plasmids into scrambled and shp38γ cells, we can 
observe the behavior of both motility components in real-time, with direct relation 
to whole cell movement and subcellular traction forces. Using these additional 
parameters, we can extend our initial cytoskeleton-based computational model of 
cell motility to begin generating a comprehensive, system-wide model of cell 
motility. 
 
Proteomic and phospho-proteomic analysis of p38γ signaling in breast 
cancer 
p38 is a well-established signaling hub capable of integrating wide-ranging inputs 
into diverse cellular responses (57); however, a systems biology view of p38 
signaling in cancer—specifically p38γ signaling—has not been established. To 
address the diverse signaling roles of p38γ in breast cancer, we will determine 
quantitative proteomic and phospho-proteomic changes in MDA-MB-231 cells 
resulting from p38γ knockdown using Stable Isotope Labeling with Amino acids 
in Cell culture (SILAC) (144). 
 
In brief, SILAC is a mass spectrometry (MS)-based technique for determining the 
relative abundance of isotopically-labeled proteins between two samples (in our 
case scrambled vs. shp38γ cells). By isotopcially-labeling the proteins in one 
sample (i.e. shp38γ) but not the other (i.e. scrambled), the MS peaks for identical 
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proteins from different samples will appear at slightly different retention times. By 
measuring the peak height for each sample the relative protein expression in one 
sample can be compared to the other. Phospho-SILAC is essentially identical to 
SILAC except that samples are enriched a priori for phosphopeptides by affinity 
purifying whole cell lysates on a phosphopeptide-binding TiO2 column (145). 
 
p38γ knockdown in MDA-MB-231 cells produces dramatic changes in cell 
behavior, from changes in cell shape and motility (Chapters 3 and 4) to changes 
in proliferation (data not shown). Since p38γ is a kinase and typically exerts its 
effects through phosphorylation of target proteins, we expect that many of its 
effects on cell behavior begin as changes in protein phosphorylation. To address 
this hypothesis, we will quantitatively determine differences in the 
phosphoproteome, and in the relative levels of phosphorylation of individual 
proteins, between scrambled and shp38γ cells using phospho-SILAC. 
 
As exemplified by the changes in RhoC expression observed in Chapter 3, p38γ 
can also indirectly affect expression of important proteins, independent of 
phosphorylation. To gain a deeper understanding of p38γ effects on cell signaling 
we will analyze relative changes in total protein levels between scrambled and 
shp38γ cells using standard SILAC.  
 
From these two datasets we can generate a systems-wide portrait of p38γ 
function in breast cancer cell behavior. By relating changes in signaling pathways 
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to the observed phenotypic effects of p38γ knockdown we can identify essential 
networks in the p38γ signaling cascade that govern the tumorigenic and 
metastatic properties of basal breast cancer cell behavior, and thus likely 
represent prime therapeutic targets. Understanding p38γ signaling at a systems-
level will also fuel hypotheses regarding p38γ function in normal breast 
development, as well as in other cancer types.  
 
Identify p38γ-specific inhibitors for therapeutic targeting 
The work presented here provides strong rationale for therapeutically targeting 
p38γ as a means of preventing breast cancer metastasis, and previous work has 
shown that inhibiting p38γ also helps sensitize cancer cells to PARP inhibitors 
(146, 147). p38γ knockout mice have no adverse effects (68), suggesting that 
inhibiting p38γ may be minimally toxic. Additionally, inhibiting p38γ in breast 
cancer cells does not result in compensatory upregulation of other p38 isoforms, 
unlike inhibition of the other p38 isoforms—a trait attributed to the limited efficacy 
of p38 inhibitors in clinical trials (68, 148, 149). Unfortunately, at present there 
are no p38γ-specific pharmacologic inhibitors (BIRB-796 does inhibit p38γ at 
high doses, but also inhibits the other four p38 isoforms (150)). 
 
Because of the high specificity required to inhibit p38γ independent of the other 
three p38 isoforms, it will be necessary to screen a large number of compounds. 
The University of Michigan Center for Chemical Genomics has over 174,000 
chemical compounds and 20,000 natural compounds on hand, as well as high 
156 
 
throughput screening capabilities. By biochemically screening for compounds 
that inhibit p38γ interaction with a downstream effector (using a mammalian two-
hybrid screen or a FRET-based screen), we can identify candidate p38γ-specific 
drugs, which can subsequently be validated in the lab through functional assays 




Figure 5.1 – RhoC regulates expression of p38γ and its upstream kinases. 
(A) Ectopic RhoC expression in MCF-10A cells increases p38γ mRNA levels to 
levels comparable to MDA-MB-231 cells. (B) p38γ protein expression is 
increased in transgenic mice that overexpress either RhoC or PyMt and RhoC. 
(C) mRNA levels of MKK3 and MKK6, both upstream p38γ kinases, are 
increased in MDA-MB-231 cells but are not affected by RhoC G14V 
overexpression. (D) RhoC overexpression increases MKK6 expression and 
MKK3/6 phosphorylation, but not MKK3 expression, in both RhoC transgenic 
mouse models. Interestingly, although RhoC expression increases MKK6 protein 





Figure 5.2 – Focal adhesions and traction forces differ between scrambled 
and shp38γ cells. (A) Total protein levels of the focal adhesion marker vinculin 
do not differ between scrambled and shp38γ cells, however focal adhesion 
distribution is significantly altered (B). (C) Traction force distribution generated by 
scrambled and shp38γ cells grown on mPADs mirrors focal adhesion distribution. 
(D) (top) Time lapse images of a scrambled cell on an mPAD undergoing a 
contractile event. The beginning and end of the contraction are labeled ―Initiation‖ 
and ―Completion‖, respectively. (bottom) Quantification of total (solid) and vector 
sum force (dashed) from time lapse images of both cell lines. Although both cell 
lines exert similar average force for both force measurements, shp38γ cells are 
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never able to exert the same maximum total force that scrambled cells reach 
during contraction (see point 2), suggesting that shp38γ cells cannot generate 




24. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et 
al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis 
and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 
2010;16:45-55. 
25. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. 
Distinct populations of cancer stem cells determine tumor growth and metastatic 
activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23. 
26. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, et al. A 
subpopulation of CD26+ cancer stem cells with metastatic capacity in human 
colorectal cancer. Cell Stem Cell. 2010;6:603-15. 
31. Le Clainche C, Carlier MF. Regulation of actin assembly associated with 
protrusion and adhesion in cell migration. Physiol Rev. 2008;88:489-513. 
40. Rosenthal DT, Brenner JC, Merajver SD. Rho Proteins in Cancer. In: van 
Golen KL, editor. The Rho GTPases in Cancer. New York: Springer New York; 
2010. p. 29-42. 
47. Wheeler AP, Ridley AJ. Why three Rho proteins? RhoA, RhoB, RhoC, and 
cell motility. Exp Cell Res. 2004;301:43-9. 
48. Ridley AJ. The GTP-binding protein Rho. Int J Biochem Cell Biol. 
1997;29:1225-9. 
51. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a 
novel transforming oncogene for human mammary epithelial cells that partially 
recapitulates the inflammatory breast cancer phenotype. Cancer Res. 
2000;60:5832-8. 
52. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of 
metastasis reveals an essential role for RhoC. Nature. 2000;406:532-5. 
53. Ikoma T, Takahashi T, Nagano S, Li YM, Ohno Y, Ando K, et al. A 
definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin 
Cancer Res. 2004;10:1192-200. 
54. Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, et al. RhoC 
expression and head and neck cancer metastasis. Mol Cancer Res. 
2009;7:1771-80. 
55. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, 
Khokha R, et al. RhoC is dispensable for embryogenesis and tumor initiation but 
essential for metastasis. Genes Dev. 2005;19:1974-9. 
57. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 
2001;410:37-40. 
68. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, Murray-Tait V, et al. 
p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating 
its interaction with GKAP. EMBO J. 2005;24:1134-45. 
69. Gillespie MA, Le Grand F, Scime A, Kuang S, von Maltzahn J, Seale V, et 
al. p38-{gamma}-dependent gene silencing restricts entry into the myogenic 
differentiation program. J Cell Biol. 2009;187:991-1005. 
161 
 
71. Tortorella LL, Lin CB, Pilch PF. ERK6 is expressed in a developmentally 
regulated manner in rodent skeletal muscle. Biochem Biophys Res Commun. 
2003;306:163-8. 
72. Cuenda A, Cohen P. Stress-activated protein kinase-2/p38 and a 
rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem. 
1999;274:4341-6. 
74. Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38 gamma: a 
new member of p38 group of MAP kinases. Biochem Biophys Res Commun. 
1996;228:334-40. 
79. Loesch M, Chen G. The p38 MAPK stress pathway as a tumor suppressor 
or more? Front Biosci. 2008;13:3581-93. 
85. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, et al. A 
novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in 
inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory 
breast cancer phenotype. Clin Cancer Res. 1999;5:2511-9. 
86. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. 
95. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase 
overexpression modulates induction of angiogenic factors in breast cells. 
Neoplasia. 2000;2:418-25. 
135. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, et al. WISP3 and 
RhoC guanosine triphosphatase cooperate in the development of inflammatory 
breast cancer. Breast Cancer Res. 2004;6:R110-5. 
136. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH. The lymphovascular 
embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am 
J Pathol. 2008;173:561-74. 
137. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, et al. 
Characterizing cancer cells with cancer stem cell-like features in 293T human 
embryonic kidney cells. Mol Cancer. 2010;9:180. 
138. Srivastava S, Ramdass B, Nagarajan S, Rehman M, Mukherjee G, 
Krishna S. Notch1 regulates the functional contribution of RhoC to cervical 
carcinoma progression. Br J Cancer. 2010;102:196-205. 
139. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura 
MJ, et al. In vitro propagation and transcriptional profiling of human mammary 
stem/progenitor cells. Genes Dev. 2003;17:1253-70. 
140. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. 
Cell. 1990;61:759-67. 
141. Remy G, Risco AM, Inesta-Vaquera FA, Gonzalez-Teran B, Sabio G, 
Davis RJ, et al. Differential activation of p38MAPK isoforms by MKK6 and MKK3. 
Cell Signal. 2010;22:660-7. 
142. Balaban NQ, Schwarz US, Riveline D, Goichberg P, Tzur G, Sabanay I, et 
al. Force and focal adhesion assembly: a close relationship studied using elastic 
micropatterned substrates. Nat Cell Biol. 2001;3:466-72. 
143. Fu J, Wang YK, Yang MT, Desai RA, Yu X, Liu Z, et al. Mechanical 
regulation of cell function with geometrically modulated elastomeric substrates. 
Nat Methods. 2010;7:733-6. 
162 
 
144. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, 
et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple 
and accurate approach to expression proteomics. Mol Cell Proteomics. 
2002;1:376-86. 
145. Thingholm TE, Jorgensen TJ, Jensen ON, Larsen MR. Highly selective 
enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc. 
2006;1:1929-35. 
146. Meng F, Zhang H, Liu G, Kreike B, Chen W, Sethi S, et al. p38gamma 
Mitogen-Activated Protein Kinase Contributes to Oncogenic Properties 
Maintenance and Resistance to Poly (ADP-Ribose)-Polymerase-1 Inhibition in 
Breast Cancer. Neoplasia. 2011;13:472-82. 
147. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al. A synthetic 
lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. 
EMBO J. 2008;27:1368-77. 
148. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK 
pathway. Trends Pharmacol Sci. 2007;28:286-95. 
149. O'Keefe SJ, Mudgett JS, Cupo S, Parsons JN, Chartrain NA, Fitzgerald C, 
et al. Chemical genetics define the roles of p38alpha and p38beta in acute and 
chronic inflammation. J Biol Chem. 2007;282:34663-71. 
150. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A. BIRB796 






Full Reference List 
1. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse 
SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, 
Chen HS, Feuer EJ, Cronin KA, Edwards BK. SEER Cancer Statistics Review, 
1975-2008. Bethesda, MD: National Cancer Institute; 2011. 
2. Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast 
tumor progression. Front Biosci. 2010;15:226-36. 
3. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor 
progression? J Mammary Gland Biol Neoplasia. 2005;10:231-47. 
4. Martin GR, Timpl R. Laminin and other basement membrane components. 
Annu Rev Cell Biol. 1987;3:57-85. 
5. Wiseman BS, Werb Z. Stromal effects on mammary gland development 
and breast cancer. Science. 2002;296:1046-9. 
6. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell 
migration, invasion, and metastasis. Cell. 2006;124:263-6. 
7. Bockhorn M, Jain RK, Munn LL. Active versus passive mechanisms in 
metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet 
Oncol. 2007;8:444-8. 
8. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. 
Detection and characterization of carcinoma cells in the blood. Proc Natl Acad 
Sci U S A. 1998;95:4589-94. 
9. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez 
M, Campos M, et al. Detection of breast cancer cells in the peripheral blood is 
positively correlated with estrogen-receptor status and predicts for poor 
prognosis. Int J Cancer. 2003;107:984-90. 
10. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. 
Circulating tumor cells, disease progression, and survival in metastatic breast 
cancer. N Engl J Med. 2004;351:781-91. 
11. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the 
crossroads of development and tumor metastasis. Dev Cell. 2008;14:818-29. 
12. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal 
transitions in development and disease. Cell. 2009;139:871-90. 
13. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat 
Rev Cancer. 2002;2:442-54. 
14. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal 
transition: new insights in signaling, development, and disease. J Cell Biol. 
2006;172:973-81. 
15. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et 
al. Twist, a master regulator of morphogenesis, plays an essential role in tumor 
metastasis. Cell. 2004;117:927-39. 
16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. 
Molecular portraits of human breast tumours. Nature. 2000;406:747-52. 
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 
U S A. 2003;100:3983-8. 
164 
 
18. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, 
et al. ALDH1 is a marker of normal and malignant human mammary stem cells 
and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555-67. 
19. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev 
Cancer. 2005;5:275-84. 
20. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol. 
2010;4:404-19. 
21. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The 
epithelial-mesenchymal transition generates cells with properties of stem cells. 
Cell. 2008;133:704-15. 
22. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The 
prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl 
J Med. 2007;356:217-26. 
23. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, et al. Cancer 
stem cells from human breast tumors are involved in spontaneous metastases in 
orthotopic mouse models. Proc Natl Acad Sci U S A. 2010;107:18115-20. 
24. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et 
al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis 
and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 
2010;16:45-55. 
25. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. 
Distinct populations of cancer stem cells determine tumor growth and metastatic 
activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23. 
26. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, et al. A 
subpopulation of CD26+ cancer stem cells with metastatic capacity in human 
colorectal cancer. Cell Stem Cell. 2010;6:603-15. 
27. Lewis AK, Bridgman PC. Nerve growth cone lamellipodia contain two 
populations of actin filaments that differ in organization and polarity. J Cell Biol. 
1992;119:1219-43. 
28. Machesky LM. Lamellipodia and filopodia in metastasis and invasion. 
FEBS Lett. 2008;582:2102-11. 
29. Ponti A, Machacek M, Gupton SL, Waterman-Storer CM, Danuser G. Two 
distinct actin networks drive the protrusion of migrating cells. Science. 
2004;305:1782-6. 
30. Gupton SL, Anderson KL, Kole TP, Fischer RS, Ponti A, Hitchcock-
DeGregori SE, et al. Cell migration without a lamellipodium: translation of actin 
dynamics into cell movement mediated by tropomyosin. J Cell Biol. 
2005;168:619-31. 
31. Le Clainche C, Carlier MF. Regulation of actin assembly associated with 
protrusion and adhesion in cell migration. Physiol Rev. 2008;88:489-513. 
32. Zamir E, Geiger B. Components of cell-matrix adhesions. J Cell Sci. 
2001;114:3577-9. 
33. Burridge K, Fath K, Kelly T, Nuckolls G, Turner C. Focal adhesions: 
transmembrane junctions between the extracellular matrix and the cytoskeleton. 
Annu Rev Cell Biol. 1988;4:487-525. 
165 
 
34. Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and 
signaling. Annu Rev Cell Dev Biol. 1996;12:463-518. 
35. Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and 
turnover in migrating cells -- over and over and over again. Nat Cell Biol. 
2002;4:E97-100. 
36. Ezratty EJ, Partridge MA, Gundersen GG. Microtubule-induced focal 
adhesion disassembly is mediated by dynamin and focal adhesion kinase. Nat 
Cell Biol. 2005;7:581-90. 
37. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et 
al. Cell migration: integrating signals from front to back. Science. 2003;302:1704-
9. 
38. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated 
molecular process. Cell. 1996;84:359-69. 
39. Ridley AJ. Rho GTPases and cell migration. J Cell Sci. 2001;114:2713-22. 
40. Rosenthal DT, Brenner JC, Merajver SD. Rho Proteins in Cancer. In: van 
Golen KL, editor. The Rho GTPases in Cancer. New York: Springer New York; 
2010. p. 29-42. 
41. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small 
GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 
1992;70:401-10. 
42. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the 
assembly of focal adhesions and actin stress fibers in response to growth factors. 
Cell. 1992;70:389-99. 
43. Chimini G, Chavrier P. Function of Rho family proteins in actin dynamics 
during phagocytosis and engulfment. Nat Cell Biol. 2000;2:E191-6. 
44. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 
2002;420:629-35. 
45. Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der 
Kammen RA, et al. Rho family proteins in cell adhesion and cell migration. Eur J 
Cancer. 2000;36:1269-74. 
46. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev 
Biol. 2004;265:23-32. 
47. Wheeler AP, Ridley AJ. Why three Rho proteins? RhoA, RhoB, RhoC, and 
cell motility. Exp Cell Res. 2004;301:43-9. 
48. Ridley AJ. The GTP-binding protein Rho. Int J Biochem Cell Biol. 
1997;29:1225-9. 
49. Wu M, Wu ZF, Rosenthal DT, Rhee EM, Merajver SD. Characterization of 
the roles of RhoC and RhoA GTPases in invasion, motility, and matrix adhesion 
in inflammatory and aggressive breast cancers. Cancer. 2010;116:2768-82. 
50. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, et 
al. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies 
RhoC as a prognostic marker of colon carcinoma. Oncogene. 2006;25:6959-67. 
51. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a 
novel transforming oncogene for human mammary epithelial cells that partially 




52. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of 
metastasis reveals an essential role for RhoC. Nature. 2000;406:532-5. 
53. Ikoma T, Takahashi T, Nagano S, Li YM, Ohno Y, Ando K, et al. A 
definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin 
Cancer Res. 2004;10:1192-200. 
54. Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, et al. RhoC 
expression and head and neck cancer metastasis. Mol Cancer Res. 
2009;7:1771-80. 
55. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, 
Khokha R, et al. RhoC is dispensable for embryogenesis and tumor initiation but 
essential for metastasis. Genes Dev. 2005;19:1974-9. 
56. van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD. Mitogen 
activated protein kinase pathway is involved in RhoC GTPase induced motility, 
invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis. 
2002;19:301-11. 
57. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 
2001;410:37-40. 
58. Raman M, Chen W, Cobb MH. Differential regulation and properties of 
MAPKs. Oncogene. 2007;26:3100-12. 
59. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK 
pathways in cancer development. Nat Rev Cancer. 2009;9:537-49. 
60. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function 
and role in human diseases. Biochim Biophys Acta. 2007;1773:1358-75. 
61. Wang Y, Huang S, Sah VP, Ross J, Jr., Brown JH, Han J, et al. Cardiac 
muscle cell hypertrophy and apoptosis induced by distinct members of the p38 
mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161-8. 
62. Platanias LC. Map kinase signaling pathways and hematologic 
malignancies. Blood. 2003;101:4667-79. 
63. Qi X, Pohl NM, Loesch M, Hou S, Li R, Qin JZ, et al. p38alpha 
antagonizes p38gamma activity through c-Jun-dependent ubiquitin-proteasome 
pathways in regulating Ras transformation and stress response. J Biol Chem. 
2007;282:31398-408. 
64. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. 
Trends Pharmacol Sci. 2002;23:40-5. 
65. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, et al. 
p38delta Mitogen-activated protein kinase is essential for skin tumor 
development in mice. Cancer Res. 2009;69:4648-55. 
66. Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, 
et al. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate 
invasion and growth of head and neck squamous carcinoma cells. Oncogene. 
2007;26:5267-79. 
67. Efimova T. p38delta mitogen-activated protein kinase regulates skin 
homeostasis and tumorigenesis. Cell Cycle. 2010;9:498-05. 
68. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, Murray-Tait V, et al. 
p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating 
its interaction with GKAP. EMBO J. 2005;24:1134-45. 
167 
 
69. Gillespie MA, Le Grand F, Scime A, Kuang S, von Maltzahn J, Seale V, et 
al. p38-{gamma}-dependent gene silencing restricts entry into the myogenic 
differentiation program. J Cell Biol. 2009;187:991-1005. 
70. Cuenda A, Cohen P, Buee-Scherrer V, Goedert M. Activation of stress-
activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is 
mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and 
SAPK2 (RK/p38). EMBO J. 1997;16:295-305. 
71. Tortorella LL, Lin CB, Pilch PF. ERK6 is expressed in a developmentally 
regulated manner in rodent skeletal muscle. Biochem Biophys Res Commun. 
2003;306:163-8. 
72. Cuenda A, Cohen P. Stress-activated protein kinase-2/p38 and a 
rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem. 
1999;274:4341-6. 
73. Wang XS, Diener K, Manthey CL, Wang S, Rosenzweig B, Bray J, et al. 
Molecular cloning and characterization of a novel p38 mitogen-activated protein 
kinase. J Biol Chem. 1997;272:23668-74. 
74. Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38 gamma: a 
new member of p38 group of MAP kinases. Biochem Biophys Res Commun. 
1996;228:334-40. 
75. Sabio G, Reuver S, Feijoo C, Hasegawa M, Thomas GM, Centeno F, et 
al. Stress- and mitogen-induced phosphorylation of the synapse-associated 
protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2. 
Biochem J. 2004;380:19-30. 
76. Sabio G, Cerezo-Guisado MI, Del Reino P, Inesta-Vaquera FA, Rousseau 
S, Arthur JS, et al. p38gamma regulates interaction of nuclear PSF and RNA with 
the tumour-suppressor hDlg in response to osmotic shock. J Cell Sci. 
2010;123:2596-604. 
77. Hasegawa M, Cuenda A, Spillantini MG, Thomas GM, Buee-Scherrer V, 
Cohen P, et al. Stress-activated protein kinase-3 interacts with the PDZ domain 
of alpha1-syntrophin. A mechanism for specific substrate recognition. J Biol 
Chem. 1999;274:12626-31. 
78. Tang J, Qi X, Mercola D, Han J, Chen G. Essential role of p38gamma in 
K-Ras transformation independent of phosphorylation. J Biol Chem. 
2005;280:23910-7. 
79. Loesch M, Chen G. The p38 MAPK stress pathway as a tumor suppressor 
or more? Front Biosci. 2008;13:3581-93. 
80. Hou SW, Zhi HY, Pohl N, Loesch M, Qi XM, Li RS, et al. PTPH1 
dephosphorylates and cooperates with p38gamma MAPK to increase ras 
oncogenesis through PDZ-mediated interaction. Cancer Res. 2010;70:2901-10. 
81. Qi X, Tang J, Loesch M, Pohl N, Alkan S, Chen G. p38gamma mitogen-
activated protein kinase integrates signaling crosstalk between Ras and estrogen 
receptor to increase breast cancer invasion. Cancer Res. 2006;66:7540-7. 
82. Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, et al. p38{gamma} 




83. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and 
cancer stem cells. Nature. 2001;414:105-11. 
84. Clevers H. The cancer stem cell: premises, promises and challenges. Nat 
Med. 2011;17:313-9. 
85. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, et al. A 
novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in 
inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory 
breast cancer phenotype. Clin Cancer Res. 1999;5:2511-9. 
86. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. 
87. Dietrich KA, Schwarz R, Liska M, Grass S, Menke A, Meister M, et al. 
Specific induction of migration and invasion of pancreatic carcinoma cells by 
RhoC, which differs from RhoA in its localisation and activity. Biol Chem. 
2009;390:1063-77. 
88. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-
dimensional cultures. Nat Rev Cancer. 2005;5:675-88. 
89. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models 
of normal and malignant breast epithelial cells. Nat Methods. 2007;4:359-65. 
90. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, et al. 
The morphologies of breast cancer cell lines in three-dimensional assays 
correlate with their profiles of gene expression. Mol Oncol. 2007;1:84-96. 
91. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. 
Identification of a cancer stem cell in human brain tumors. Cancer Res. 
2003;63:5821-8. 
92. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective 
identification of tumorigenic prostate cancer stem cells. Cancer Res. 
2005;65:10946-51. 
93. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the 
mammary stem/progenitor cell population driving tumorigenesis and invasion. 
Oncogene. 2008;27:6120-30. 
94. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, et al. 
RhoC-GTPase is a novel tissue biomarker associated with biologically 
aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005;93:101-10. 
95. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase 
overexpression modulates induction of angiogenic factors in breast cells. 
Neoplasia. 2000;2:418-25. 
96. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et 
al. Identification of selective inhibitors of cancer stem cells by high-throughput 
screening. Cell. 2009;138:645-59. 
97. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. 
Biophotonics International. 2004;11:36-42. 
98. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays 
(TMAs) for high-throughput molecular pathology research. Int J Cancer. 
2001;94:1-5. 
99. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative 
analysis (AQUA) of in situ protein expression, antibody concentration, and 
prognosis. J Natl Cancer Inst. 2005;97:1808-15. 
169 
 
100. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma 
in situ of the breast. N Engl J Med. 2004;350:1430-41. 
101. Cohen P. The search for physiological substrates of MAP and SAP 
kinases in mammalian cells. Trends Cell Biol. 1997;7:353-61. 
102. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-
activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and 
MKK6. J Biol Chem. 1998;273:1741-8. 
103. Ladwein M, Rottner K. On the Rho'd: the regulation of membrane 
protrusions by Rho-GTPases. FEBS Lett. 2008;582:2066-74. 
104. Rajah TT, Abidi SM, Rambo DJ, Dmytryk JJ, Pento JT. The motile 
behavior of human breast cancer cells characterized by time-lapse 
videomicroscopy. In Vitro Cell Dev Biol Anim. 1998;34:626-8. 
105. Partin AW, Schoeniger JS, Mohler JL, Coffey DS. Fourier analysis of cell 
motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A. 
1989;86:1254-8. 
106. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibers, lamellipodia, 
and filopodia. Cell. 1995;81:53-62. 
107. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A 
comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical 
prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. 
Clin Cancer Res. 2010;16:5222-32. 
108. Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated 
protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase 
secretion and in vitro invasion. Cancer Res. 1998;58:1135-9. 
109. Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, et al. 
Inhibition of the p38 kinase suppresses the proliferation of human ER-negative 
breast cancer cells. Cancer Res. 2009;69:8853-61. 
110. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio 
MG, et al. The transcription factor snail controls epithelial-mesenchymal 
transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76-83. 
111. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 
2008;359:2814-23. 
112. Rosenthal DT, Iyer H, Escudero SE, Wu Z, Bao L, Garcia H, et al. 
Computational mechanical modeling reveals the role of p38γ in shaping the 
cytoskeleton and controlling locomotion of aggressive breast cancer cells. 
Cancer Research. 2011;Concurrent Submission. 
113. Wu M, Wu ZF, Merajver SD. Rho proteins and cell-matrix interactions in 
cancer. Cells Tissues Organs. 2007;185:100-3. 
114. Nethe M, Hordijk PL. The role of ubiquitylation and degradation in 
RhoGTPase signalling. J Cell Sci. 2010;123:4011-8. 
115. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. 
Characterization of RhoC expression in benign and malignant breast disease: a 




116. Weinberg RA. The Biology of Cancer. 1 ed. New York, NY: Garland 
Science; 2007. 
117. Thiery JP. Epithelial-mesenchymal transitions in development and 
pathologies. Curr Opin Cell Biol. 2003;15:740-6. 
118. Rosenthal DT, Escudero SE, Bao L, Wu Z, Merajver SD. p38γ drives 
breast cancer cell motility and metastasis through regulation of RhoC GTPase. 
Cancer Research. 2011;Concurrent Submission. 
119. Phillips R, Kondev J, Theriot J. Physical biology of the cell. New York: 
Garland Science; 2009. 
120. Barnhart EL, Allen GM, Julicher F, Theriot JA. Bipedal locomotion in 
crawling cells. Biophys J. 2010;98:933-42. 
121. Ehrengruber MU, Coates TD, Deranleau DA. Shape oscillations: a 
fundamental response of human neutrophils stimulated by chemotactic peptides? 
FEBS Lett. 1995;359:229-32. 
122. Mogilner A. On the edge: modeling protrusion. Curr Opin Cell Biol. 
2006;18:32-9. 
123. Peskin CS, Odell GM, Oster GF. Cellular motions and thermal 
fluctuations: the Brownian ratchet. Biophys J. 1993;65:316-24. 
124. Mogilner A, Oster G. Force generation by actin polymerization II: the 
elastic ratchet and tethered filaments. Biophys J. 2003;84:1591-605. 
125. Dickinson RB, Caro L, Purich DL. Force generation by cytoskeletal 
filament end-tracking proteins. Biophys J. 2004;87:2838-54. 
126. Dickinson RB, Purich DL. Clamped-filament elongation model for actin-
based motors. Biophys J. 2002;82:605-17. 
127. Plastino J, Sykes C. The actin slingshot. Curr Opin Cell Biol. 2005;17:62-
6. 
128. Gerbal F, Chaikin P, Rabin Y, Prost J. An elastic analysis of Listeria 
monocytogenes propulsion. Biophys J. 2000;79:2259-75. 
129. Bernheim-Groswasser A, Prost J, Sykes C. Mechanism of actin-based 
motility: a dynamic state diagram. Biophys J. 2005;89:1411-9. 
130. Del Alamo JC, Meili R, Alonso-Latorre B, Rodriguez-Rodriguez J, Aliseda 
A, Firtel RA, et al. Spatio-temporal analysis of eukaryotic cell motility by improved 
force cytometry. Proc Natl Acad Sci U S A. 2007;104:13343-8. 
131. Timoshenko S, Goodier J. Theory of Elasticity. New York: McGraw-Hill; 
1951. 
132. Hughes TJR. Linear Static and Dynamic Finite Element Analysis 
Mineola, NY: Dover Publications; 2000. 
133. Svitkina TM, Verkhovsky AB, McQuade KM, Borisy GG. Analysis of the 
actin-myosin II system in fish epidermal keratocytes: mechanism of cell body 
translocation. J Cell Biol. 1997;139:397-415. 
134. Pollard TD, Cooper JA. Actin, a central player in cell shape and 
movement. Science. 2009;326:1208-12. 
135. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, et al. WISP3 and 
RhoC guanosine triphosphatase cooperate in the development of inflammatory 
breast cancer. Breast Cancer Res. 2004;6:R110-5. 
171 
 
136. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH. The lymphovascular 
embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am 
J Pathol. 2008;173:561-74. 
137. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, et al. 
Characterizing cancer cells with cancer stem cell-like features in 293T human 
embryonic kidney cells. Mol Cancer. 2010;9:180. 
138. Srivastava S, Ramdass B, Nagarajan S, Rehman M, Mukherjee G, 
Krishna S. Notch1 regulates the functional contribution of RhoC to cervical 
carcinoma progression. Br J Cancer. 2010;102:196-205. 
139. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura 
MJ, et al. In vitro propagation and transcriptional profiling of human mammary 
stem/progenitor cells. Genes Dev. 2003;17:1253-70. 
140. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. 
Cell. 1990;61:759-67. 
141. Remy G, Risco AM, Inesta-Vaquera FA, Gonzalez-Teran B, Sabio G, 
Davis RJ, et al. Differential activation of p38MAPK isoforms by MKK6 and MKK3. 
Cell Signal. 2010;22:660-7. 
142. Balaban NQ, Schwarz US, Riveline D, Goichberg P, Tzur G, Sabanay I, et 
al. Force and focal adhesion assembly: a close relationship studied using elastic 
micropatterned substrates. Nat Cell Biol. 2001;3:466-72. 
143. Fu J, Wang YK, Yang MT, Desai RA, Yu X, Liu Z, et al. Mechanical 
regulation of cell function with geometrically modulated elastomeric substrates. 
Nat Methods. 2010;7:733-6. 
144. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, 
et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple 
and accurate approach to expression proteomics. Mol Cell Proteomics. 
2002;1:376-86. 
145. Thingholm TE, Jorgensen TJ, Jensen ON, Larsen MR. Highly selective 
enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc. 
2006;1:1929-35. 
146. Meng F, Zhang H, Liu G, Kreike B, Chen W, Sethi S, et al. p38gamma 
Mitogen-Activated Protein Kinase Contributes to Oncogenic Properties 
Maintenance and Resistance to Poly (ADP-Ribose)-Polymerase-1 Inhibition in 
Breast Cancer. Neoplasia. 2011;13:472-82. 
147. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al. A synthetic 
lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. 
EMBO J. 2008;27:1368-77. 
148. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK 
pathway. Trends Pharmacol Sci. 2007;28:286-95. 
149. O'Keefe SJ, Mudgett JS, Cupo S, Parsons JN, Chartrain NA, Fitzgerald C, 
et al. Chemical genetics define the roles of p38alpha and p38beta in acute and 
chronic inflammation. J Biol Chem. 2007;282:34663-71. 
150. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A. BIRB796 
inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem. 2005;280:19472-
9. 
 
